Patent Application
20220235135
The instant application contains a Sequence Listing which has been submitted via EFS-Web and is hereby incorporated herein by reference in its entirety. Said ASCII copy, created on Apr. 9, 2020, is named 42700WO_CRF_sequencelisting.txt, and is 389,339 bytes in size.
Immune therapy has great potential for the treatment of cancer. However, tumors can become resistant to immune therapy, for example by recruiting immunosuppressive cells or signaling molecules to the tumor microenvironment or by co-opting immune checkpoint signaling pathways.
Galectin-9 (GAL9) is an S-type lectin beta-galactoside-binding protein with N- and C-terminal carbohydrate-binding domains connected by a linker peptide. GAL9 has been implicated in modulating cell-cell and cell-matrix interactions. GAL9 has been shown to bind soluble PD-L2, and at least some of the immunological effects of PD-L2 have been suggested to be mediated through binding of multimeric PD-L2 to GAL9, rather than through PD-1 (WO 2016/008005, which is incorporated herein by reference in its entirety). However, mechanisms by which GAL9 and PD-L2 impact immune effector function are not yet fully characterized.
There remains a need for therapeutic agents that can enhance immune effector function and reduce immunosuppressive or T cell exhaustion pathways. Such therapeutic agents may be useful for improving cancer immune therapy.
In a first aspect the disclosure provides a Galectin-9 (GAL9) antigen binding molecule comprising a first antigen binding site specific (ABS) for a first epitope of a first GAL9 antigen, wherein the first antigen binding site comprises all three VH CDRs from any one of the ABS clones selected from P9-02B, P9-04, P9-05, P9-08, P9-09, P9-10, P9-15, P9-16, P9-18, P9-19, P9-20, P9-21, P9-22, P9-27, P9-28, P9-31, P9-32, P9-36, P9-39, P9-49, P9-54, and P9-58.
In a second aspect, the disclosure provides a Galectin-9 (GAL9) antigen binding molecule, comprising a first antigen binding site specific for a first epitope of a first GAL9 antigen, wherein the first antigen binding site comprises all three VL CDRs from any one of the ABS clones selected from P9-02B, P9-04, P9-05, P9-08, P9-09, P9-10, P9-15, P9-16, P9-18, P9-19, P9-20, P9-21, P9-22, P9-27, P9-28, P9-31, P9-32, P9-36, P9-39, P9-49, P9-54, and P9-58.
In a third aspect, the disclosure provides a Galectin-9 (GAL9) antigen binding molecule, comprising a first antigen binding site specific for a first epitope of a first GAL9 antigen, wherein the first antigen binding site comprises all three VH CDRs and all three VL CDRs from any one of the ABS clones selected from P9-02B, P9-04, P9-05, P9-08, P9-09, P9-10, P9-15, P9-16, P9-18, P9-19, P9-20, P9-21, P9-22, P9-27, P9-28, P9-31, P9-32, P9-36, P9-39, P9-49, P9-54, and P9-58.
In a fourth aspect, the disclosure provides a Galectin-9 (GAL9) antigen binding molecule, comprising a first antigen binding site specific for a first epitope of a first GAL9 antigen, comprising the VL sequence and the VH sequence from any one of the ABS clones selected from P9-02B, P9-04, P9-05, P9-08, P9-09, P9-10, P9-15, P9-16, P9-18, P9-19, P9-20, P9-21, P9-22, P9-27, P9-28, P9-31, P9-32, P9-36, P9-39, P9-49, P9-54, and P9-58.
In some embodiments, the GAL9 antigen binding molecule comprises a full immunoglobulin heavy chain “IgG1” sequence comprising the VH sequence and a full immunoglobulin light chain sequence comprising the VL sequence, wherein the VH sequence and the VL sequence are from any one of the ABS clones selected from P9-02B, P9-04, P9-05, P9-08, P9-09, P9-10, P9-15, P9-16, P9-18, P9-19, P9-20, P9-21, P9-22, P9-27, P9-28, P9-31, P9-32, P9-36, P9-39, P9-49, P9-54, and P9-58.
In some embodiments, the GAL9 antigen binding molecule comprises a full immunoglobulin heavy chain “IgG4” sequence comprising the VH sequence and a full immunoglobulin light chain sequence comprising the VL sequence, wherein the VH sequence and the VL sequence are from any one of the ABS clones selected from P9-02B, P9-04, P9-05, P9-08, P9-09, P9-10, P9-15, P9-16, P9-18, P9-19, P9-20, P9-21, P9-22, P9-27, P9-28, P9-31, P9-32, P9-36, P9-39, P9-49, P9-54, and P9-58.
In some embodiments, the GAL9 antigen binding molecule comprises a full immunoglobulin heavy chain “IgG3” sequence comprising the VH sequence and a full immunoglobulin light chain sequence comprising the VL sequence, wherein the VH sequence and the VL sequence are from any one of the ABS clones selected from P9-02B, P9-04, P9-05, P9-08, P9-09, P9-10, P9-15, P9-16, P9-18, P9-19, P9-20, P9-21, P9-22, P9-27, P9-28, P9-31, P9-32, P9-36, P9-39, P9-49, P9-54, and P9-58.
In some embodiments, the GAL9 antigen binding molecule can comprise a GAL9 antigen that is a human GAL9 antigen.
In some embodiments, the GAL9 antigen binding molecule can further comprises a second antigen binding site.
In certain embodiments, the second antigen binding site is specific for the GAL9 antigen. In other embodiments, the second antigen binding site is identical to the first antigen binding site.
In other embodiments, the second antigen binding site is specific for a second epitope of the first GAL9 antigen.
In some embodiments, the second antigen binding site comprises all three VH CDRs, all three VL CDRs, or all three VH CDRs and all three VL CDRs from another ABS clone selected from P9-02B, P9-04, P9-05, P9-08, P9-09, P9-10, P9-15, P9-16, P9-18, P9-19, P9-20, P9-21, P9-22, P9-27, P9-28, P9-31, P9-32, P9-36, P9-39, P9-49, P9-54, and P9-58.
In some embodiments, the second antigen binding site comprises the VL sequence and the VH sequence from the other ABS clone.
In some embodiments, the second antigen binding site comprises a full immunoglobulin heavy chain sequence comprising the VH sequence and a full immunoglobulin light chain sequence comprising the VL sequence from the other ABS clone.
In some embodiments, the second antigen binding site is specific for an antigen other than the first GAL9 antigen.
In some embodiments, the first antigen binding site comprises all three VH CDRs, all three VL CDRs, or all three VH CDRs and all three VL CDRs from any one of the ABS clones selected from: P9-02B, P9-04, P9-05, P9-08, P9-09, P9-10, P9-15, P9-16, P9-18, P9-19, P9-20, P9-21, P9-22, P9-27, P9-28, P9-31, P9-32, P9-36, P9-39, P9-49, P9-54, and P9- 58.
In some embodiments, the first antigen binding site comprises all three VH CDRs, all three VL CDRs, or all three VH CDRs and all three VL CDRs from any one of the ABS clones selected from: P9-18, P9-15, P9-21, and P9-28.
In some embodiments the first antigen binding site comprises all three VH CDRs, all three VL CDRs, or all three VH CDRs and all three VL CDRs from ABS clone P9-15.
In some embodiments, the first antigen binding site comprises all three VH CDRs, all three VL CDRs, or all three VH CDRs and all three VL CDRs from ABS clone P9-18.
In some embodiments, the first antigen binding site comprises all three VH CDRs, all three VL CDRs, or all three VH CDRs and all three VL CDRs from ABS clone P9-21.
In some embodiments, the first antigen binding site comprises all three VH CDRs, all three VL CDRs, or all three VH CDRs and all three VL CDRs from ABS clone P9-22.
In some embodiments, the first antigen binding site comprises all three VH CDRs, all three VL CDRs, or all three VH CDRs and all three VL CDRs from ABS clone P9-28.
In some embodiments, the GAL9 antigen binding molecule comprises an antibody format selected from the group consisting of: full-length antibodies, Fab fragments, F(ab)′2 fragments, Fvs, scFvs, tandcFvs, diabodies, scDiabodies, DARTs, single chain VHH camelid antibodies, tandAbs, minibodies, and B-bodies. B-bodies are described in US pre-grant publication number US 2018/0118811, which is incorporated herein by reference in its entirety.
In some embodiments, the GAL9 antigen binding molecule increases TNF-α secretion by activated immune cells, wherein the increase is greater than an 20, 30, 40, 50, 60, 70, or 80-fold increase relative to activated immune cells treated with a control agent.
In some embodiments, the GAL9 antigen binding molecule increases IFN-γ secretion by activated immune cells, wherein the increase is greater than an 1.2-fold increase relative to activated immune cells treated with a control agent.
In some embodiments, the GAL9 antigen binding molecule increases CD40L surface expression of activated CD8+ T-cells, wherein the increase is greater than a 2-fold increase relative to activated CD8+ T-cells treated with a control agent.
In some embodiments, the GAL9 antigen binding molecule increases OX40 surface expression of Activated CD8+ T-cells, wherein the increase is greater than a 2-fold increase relative to activated CD8+ T-cells treated with a control agent.
In some embodiments, the GAL9 antigen binding molecule increases IL-12 production of activated dendritic cells (DCs), wherein the increase is greater than an 20-fold increase relative to activated DCs treated with a control agent.
In some embodiments, GAL9 antigen binding molecule increases PD-L2 surface expression on activated dendritic cells (DCs), wherein the increase is greater than an 4-fold increase relative to activated DCs treated with a control agent.
In some embodiments, the control agent is a negative control agent or positive control agent.
In some embodiments, the control agent is a control antibody.
In some embodiments, the control antibody is selected from the group consisting of: an ECA42 clone anti-GAL9 antibody, an RG9.1 clone anti-GAL9 antibody, an RG9.35 clone anti-GAL9 antibody, an anti-PD1 antibody, and a non-GAL9 binding isotype control antibody.
In some embodiments, the activated immune cells, activated CD8+ T-cells, or activated DCs were activated by peptide stimulation, e.g., by a peptide or plurality of peptides known to induce an immune response.
In a fifth aspect, the disclosure provides a GAL9 antigen binding molecule increases TNF-α secretion by activated immune cells, wherein the increase is greater than an 80-fold increase relative to activated immune cells treated with a control agent.
In a sixth aspect, the disclosure provides a GAL9 antigen binding molecule increases IFN-γ secretion by activated immune cells, wherein the increase is greater than an 1.2-fold increase relative to activated immune cells treated with a control agent.
In a seventh aspect, the disclosure provides a GAL9 antigen binding molecule increases CD40L surface expression of Activated CD8+ T-cells, wherein the increase is greater than a 2-fold increase relative to activated CD8+ T-cells treated with a control agent.
In an eighth aspect, the disclosure provides a GAL9 antigen binding molecule increases OX40 surface expression of Activated CD8+ T-cells, wherein the increase is greater than a 2-fold increase relative to activated CD8+ T-cells treated with a control agent.
In a ninth aspect, the disclosure provides a GAL9 antigen binding molecule increases IL-12 production of activated dendritic cells (DCs), wherein the increase is greater than an 20-fold increase relative to activated DCs treated with a control agent.
In a tenth aspect, the disclosure provides a GAL9 antigen binding molecule increases PD-L2 surface expression on activated dendritic cells (DCs), wherein the increase is greater than an 4-fold increase relative to activated DCs treated with a control agent.
In an eleventh aspect, the disclosure provides a GAL9 antigen binding molecule demonstrates one or more of the following properties: A) increases TNF-α secretion by activated immune cells, wherein the increase is greater than an 80-fold increase relative to activated immune cells treated with a control agent; B) increases IFN-γ secretion by activated immune cells, wherein the increase is greater than an 1.2-fold increase relative to activated immune cells treated with a control agent; C) increases CD40L surface expression of activated CD8+ T-cells, wherein the increase is greater than a 2-fold increase relative to activated CD8+ T-cells treated with a control agent; D) increases OX40 surface expression of activated CD8+ T-cells, wherein the increase is greater than a 2-fold increase relative to activated CD8+ T-cells treated with a control agent; E) increases IL-12 production of activated dendritic cells (DCs), wherein the increase is greater than an 20-fold increase relative to activated DCs treated with a control agent; F) increases PD-L2 surface expression on activated dendritic cells (DCs), wherein the increase is greater than an 4-fold increase relative to activated DCs treated with a control agent.
In some embodiments, the control agent is a negative control agent or positive control agent.
In some embodiments, the control agent is a control antibody.
In some embodiments, the control antibody is selected from the group consisting of: an ECA42 clone anti-GAL9 antibody, an RG9.1 clone anti-GAL9 antibody, an RG9.35 clone anti-GAL9 antibody, an anti-PD1 antibody, and a non-GAL9 binding isotype control antibody.
In some embodiments, the activated immune cells, activated CD8+ T-cells, or activated DCs were activated by peptide stimulation, e.g., by a peptide or plurality of peptides known to induce an immune response.
In some embodiments, the GAL9 antigen binding molecule of the fifth-eleventh aspects provided herein comprise a first antigen binding site specific for a first epitope of a first GAL9 antigen, wherein the first antigen binding site comprises all three VH CDRs and all three VL CDRs from any one of the ABS clones selected from P9-02B, P9-04, P9-05, P9-08, P9-09, P9-10, P9-15, P9-16, P9-18, P9-19, P9-20, P9-21, P9-22, P9-27, P9-28, P9-31, P9-32, P9-36, P9-39, P9-49, P9-54, and P9-58.
In some embodiments, the VL sequence and the VH sequence from any one of the ABS clones selected from P9-02B, P9-04, P9-05, P9-08, P9-09, P9-10, P9-15, P9-16, P9-18, P9-19, P9-20, P9-21, P9-22, P9-27, P9-28, P9-31, P9-32, P9-36, P9-39, P9-49, P9-54, and P9-58.
In some certain embodiments, the GAL9 antigen binding molecule comprises a full immunoglobulin heavy chain sequence comprising the VH sequence and a full immunoglobulin light chain sequence comprising the VL sequence, wherein the VH sequence and the VL sequence are from any one of the ABS clones selected from P9-02B, P9-04, P9-05, P9-08, P9-09, P9-10, P9-15, P9-16, P9-18, P9-19, P9-20, P9-21, P9-22, P9-27, P9-28, P9-31, P9-32, P9-36, P9-39, P9-49, P9-54, and P9-58.
In some embodiments, the GAL9 antigen is a human GAL9 antigen.
In some embodiments, the GAL9 antigen binding molecule further comprises a second antigen binding site.
In some embodiments, the second antigen binding site is specific for the GAL9 antigen.
The GAL9 antigen binding molecule of claim 48, wherein the second antigen binding site is identical to the first antigen binding site.
In some embodiments, the second antigen binding site is specific for a second epitope of the first GAL9 antigen.
In some embodiments, the second antigen binding site comprises all three VH CDRs and all three VL CDRs from another ABS clone selected from P9-02B, P9-04, P9-05, P9-08, P9-09, P9-10, P9-15, P9-16, P9-18, P9-19, P9-20, P9-21, P9-22, P9-27, P9-28, P9-31, P9-32, P9-36, P9-39, P9-49, P9-54, and P9-58.
In some embodiments, the second antigen binding site comprises the VL sequence and the VH sequence from the other ABS clone.
In some embodiments, the second antigen binding site comprises a full immunoglobulin heavy chain sequence comprising the VH sequence and a full immunoglobulin light chain sequence comprising the VL sequence from the other ABS clone.
In some embodiments, the second antigen binding site is specific for an antigen other than the first GAL9 antigen.
In some embodiments, the first antigen binding site comprises all three VH CDRs and all three VL CDRs from any one of the ABS clones selected from: P9-10, P9-15, P9-18, P9-21, P9-22, and P9-28.
In some embodiments, the first antigen binding site comprises all three VH CDRs and all three VL CDRs from any one of the ABS clones selected from: P9-10, P9-15, P9-18, P9-21, P9-22, and P9-28.
In some embodiments, the first antigen binding site comprises all three VH CDRs and all three VL CDRs from ABS clone P9-15.
In some embodiments, the first antigen binding site comprises all three VH CDRs and all three VL CDRs from ABS clone P9-18.
In some embodiments, the first antigen binding site comprises all three VH CDRs and all three VL CDRs from ABS clone P9-21.
In some embodiments, the first antigen binding site comprises all three VH CDRs and all three VL CDRs from ABS clone P9-22.
In some embodiments, the first antigen binding site comprises all three VH CDRs and all three VL CDRs from ABS clone P9-28.
In some embodiments, the GAL9 antigen binding molecule comprises an antibody format selected from the group consisting of: full-length antibodies, Fab fragments, Fvs, scFvs, tandem scFvs, Diabodies, scDiabodies, DARTs, tandAbs, minibodies, and B-bodies.
In a twelfth aspect, the disclosure provides a GAL9 antigen binding molecule which binds to the same epitope as a GAL9 antigen binding molecule of any one of the preceding claims.
In a thirteenth aspect, the disclosure provides a GAL9 antigen binding molecule which competes for binding with a GAL9 antigen binding molecule of any one of the preceding claims.
In some embodiments, the GAL9 antigen binding molecule is purified.
In a fourteenth aspect, the disclosure provides a pharmaceutical composition comprising the GAL9 antigen binding molecule of any one of the preceding claims and a pharmaceutically acceptable diluent.
In a fifteenth aspect, the disclosure provides a method for treating a subject with cancer, the method comprising administering a therapeutically effective amount of the pharmaceutical composition as provided herein to the subject.
In some embodiments, the cancer is selected from the group consisting of: pancreatic cancer, ovarian cancer, breast cancer, lung cancer, gastric cancer, melanoma, Ewing sarcoma, chronic lymphocytic leukemia, mantle cell lymphoma, B-ALL, hematological cancer, head and neck squamous cell carcinoma, prostate cancer, colon cancer, renal cancer, and uterine cancer.
In some embodiments, cancer is selected from the group consisting of: the breast cancer, colon cancer, lung cancer and prostate cancer, cancers of the blood and lymphatic systems (including Hodgkin's disease, leukemias, lymphomas, multiple myeloma, and Waldenstrom's disease), skin cancers (including malignant melanoma), cancers of the digestive tract (including head and neck cancers, esophageal cancer, stomach cancer, cancer of the pancreas, liver cancer, colon and rectal cancer, anal cancer), cancers of the genital and urinary systems (including kidney cancer, bladder cancer, testis cancer, prostate cancer), cancers in women (including breast cancer, ovarian cancer, gynecological cancers and choriocarcinoma) as well as in brain, bone carcinoid, nasopharyngeal, retroperitoneal, thyroid and soft tissue tumors.
In some embodiments, the cancer is a viral induced tumor caused by a cancer virus. In some embodiments, the cancer virus is a Epstein-Barr virus (EBV), Hepatitis B virus, Hepatitis C virus, Human papilloma virus, Human T-lymphotropic virus 1 (HTLV-1), Kaposi sarcoma associated-herpesvirus (KHSV), Merkel cell polyomavirus, or Cytomegalovirus.
), sFc-P9-18-IgG2a (upside-down triangle
), P9-18-IgG2a (circle
), and IgG (IgG2a) control #1 (black squares
).
), P9-18 IgG2a (circle
), and IgG (IgG2a) control #2 (black diamond
).
Unless defined otherwise, all technical and scientific terms used herein have the meaning commonly understood by a person skilled in the art to which this invention belongs. As used herein, the following terms have the meanings ascribed to them below.
By “antigen binding site” or “ABS” is meant a region of a GAL9 binding molecule that specifically recognizes or binds to a given antigen or epitope.
As used herein, the terms “treat” or “treatment” are used in their broadest accepted clinical sense. The terms include, without limitation, lessening a sign or symptom of disease; improving a sign or symptom of disease; alleviation of symptoms; diminishment of extent of disease; stabilized (i.e., not worsening) state of disease; delay or slowing of disease progression; amelioration or palliation of the disease state; remission (whether partial or total), whether detectable or undetectable; cure; prolonging survival as compared to expected survival if not receiving treatment. Unless explicitly stated otherwise, “treat” or “treatment” do not intend prophylaxis or prevention of disease.
By “subject” or “individual” or “animal” or “patient” or “mammal,” is meant any subject, particularly a mammalian subject, for whom diagnosis, prognosis, or therapy is desired. Mammalian subjects include humans, domestic animals, farm animals, and zoo, sports, or pet animals such as dogs, cats, guinea pigs, rabbits, rats, mice, horses, cattle, cows, and so on. Unless otherwise stated, “patient” intends a human “subject.”
The term “sufficient amount” means an amount sufficient to produce a desired effect, e.g., an amount sufficient to modulate protein aggregation in a cell.
The term “therapeutically effective amount” is an amount that is effective to ameliorate a symptom of a disease.
The term “prophylactically effective amount” is an amount that is effective to prevent a symptom of a disease.
Unless otherwise specified, all references to sequences herein are to amino acid sequences.
Unless otherwise specified, antibody constant region residue numbering is according to the Eu index as described at www.imgt.org/IMGTScientificChart/Numbering/Hu_IGHGnber.html#refs (accessed Aug. 22, 2017), which is hereby incorporated by reference in its entirety, and residue numbers identify the residue according to its location in an endogenous constant region sequence regardless of the residue's physical location within a chain of the GAL9 binding molecules described herein.
Unless otherwise specified as “Kabat CDR”, “Chothia CDR”, “Contact CDR”, or “IMGT CDR”, all references to “CDRs” are to CDRs defined using the Martin (AbM) definition.
By “endogenous sequence” or “native sequence” is meant any sequence, including both nucleic acid and amino acid sequences, which originates from an organism, tissue, or cell and has not been artificially modified or mutated.
Polypeptide chain numbers (e.g., a “first” polypeptide chains, a “second” polypeptide chain. etc. or polypeptide “chain 1,” “chain 2,” etc.) are used herein as a unique identifier for specific polypeptide chains that form a binding molecule and is not intended to connote order or quantity of the different polypeptide chains within the binding molecule.
In this disclosure, “comprises,” “comprising,” “containing,” “having,” “includes,” “including,” and linguistic variants thereof have the meaning ascribed to them in U.S. Patent law, permitting the presence of additional components beyond those explicitly recited.
As used herein, the singular forms “a,” “an,” and “the” include the plural referents unless the context clearly indicates otherwise. The terms “include,” “such as,” and the like are intended to convey inclusion without limitation, unless otherwise specifically indicated.
Ranges provided herein are understood to be shorthand for all of the values within the range, inclusive of the recited endpoints. For example, a range of 1 to 50 is understood to include any number, combination of numbers, or sub-range from the group consisting of 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, and 50.
Unless specifically stated or otherwise apparent from context, as used herein the term “about” is understood as within a range of normal tolerance in the art, for example within 2 standard deviations of the mean. About can be understood as within 10%, 9%, 8%, 7%, 6%, 5%, 4%, 3%, 2%, 1%, 0.5%, 0.1%, 0.05%, or 0.01% of the stated value.
The present disclosure provides Galectin-9 (GAL9) antigen binding molecules, such as anti-GAL9 antibodies and antigen-binding fragments thereof, compositions comprising the GAL9-binding molecules; and pharmaceutical compositions comprising the GAL9-binding molecules. The disclosure particularly provides various GAL9 antigen binding molecules that are stimulatory, acting as activators of the immune system, increasing secretion and production of various cytokines in various immune cells and increasing surface expression of stimulatory molecules.
Also provided by the disclosure are methods of treating a disease or condition in a subject by administering an immune-stimulatory Galectin-9 antibody binding molecule. The methods provided by the disclosure are particularly useful for the treatment of a proliferative disease or cancer. In some embodiments, the cancer is a viral-induced cancer, for example, a cancer caused by an infection by an oncovirus or tumor virus. In some embodiments, the compositions and methods provided by the disclosure can be used for the treatment of a disease or condition that is immunosuppressive, such as malaria, HIV or AIDs, or the like.
In a first aspect, antigen binding molecules are provided. In every embodiment, the antigen binding molecule includes at least a first antigen binding site specific for a GAL9 antigen; the binding molecules are therefore termed GAL9 antigen binding molecules or GAL9 binding molecules.
The GAL9 antigen binding molecules described herein bind specifically to GAL9 antigens.
As used herein, “GAL9 antigens” refer to Galectin-9 family members and homologs. GAL9 is also referred to as LGALS9, HUAT, LGALS9A, tumor antigen HOM-HD-21, and ecalectin. In particular embodiments, the GAL9 binding molecule has antigen binding sites that specifically bind to at least a portion of more than one GAL9 domain, such as the junction between a first and a second GAL9 domain.
In specific embodiments, the GAL9 antigen is human. GenBank Accession #NP_033665.1 describes a canonical human GAL9 protein, including its sequences and domain features, and is hereby incorporated by reference in its entirety. SEQ ID NO:6 provides the full-length GAL9 protein sequence.
In various embodiments, the GAL9 binding molecule additionally binds specifically to at least one antigen additional to a GAL9 antigen.
In some embodiments, upon contact therewith, the GAL9 antigen binding molecule increases cytokine secretion by activated immune cells, e.g., activated human immune cells. In some embodiments, the immune cells are peripheral blood mononuclear cells (PBMCs). In some embodiments, the immune cells are T cells. In some embodiments, the T cells are effector T cells. In some embodiments, the T cells are CD8+ T cells. In some embodiments, the T cells are CD4+ T cells. In some embodiments, the immune cells are natural killer (NK) cells. In some embodiments, the immune cells are dendritic cells (DC).
The impact of the GAL9 antigen binding molecule on immune cell cytokine secretion may be determined by any suitable means. For instance, the impact of the GAL9 antigen binding molecule on immune cell cytokine secretion may be determined in vivo, ex vivo, or in vitro. In some embodiments, cytokine secretion is determined in activated immune cells contacted with a GAL9 antigen binding molecule, as compared to activated immune cells contacted with a control agent, e.g., a control antigen binding molecule or vehicle control. The immune cells may be activated by peptide stimulation. For example, the immune cells may be activated by a peptide or plurality of peptides known to induce an immune response. The control agent can be a negative control or a positive control. In some embodiments, the GAL9 antigen binding molecule increases cytokine secretion in immune cells, relative to a negative control agent or negative control antigen binding molecule. In some embodiments, the negative control antigen binding molecule is an isotype control binding molecule that does not bind GAL9. In some embodiments, the positive control antibody is an anti-PD1 antibody, such as nivolumab. In some embodiments, the positive control antibody is a GAL9 control antibody. The GAL9 control antibody can be Gal9 antibody clone RG9.1 (Cat. No. BE0218, InVivoMab Antibodies) or RG9.35. RG9.1 and RG9.35 are both described in Fukushima A, Sumi T, Fukuda K, Kumagai N, Nishida T, et al. (2008), “Roles of galectin-9 in the development of experimental allergic conjunctivitis in mice,” Int Arch Allergy Immunol 146: 36-43, which is hereby incorporated by reference in its entirety. The GAL9 control antibody can be Gal9 antibody clone ECA42 (Cat. No. LS-C179449, LifeSpan BioScience). In some embodiments, the GAL9 antigen binding molecule increases cytokine secretion in immune cells, relative to the positive control antibody.
Cytokine secretion by the immune cells can be assessed by any suitable means. By way of example only, cytokine secretion by in vitro or ex vivo immune cell culture models may be assessed by analyzing cytokine content of the cultured cell supernatants, e.g., by cytokine bead array.
In some embodiments, the cytokine is IFN-γ. In some embodiments, the GAL9 antigen binding molecule increases IFN-γ secretion in activated immune cells by at least 10%, 15%, 20%, 25%, 30%, 35%, 40%, 45%, 50%, 55%, 60%, 65%. 70%, 75%, 80%, 85%, 90%, 95%, 100%. 105%, 110%. 115%, or 120%. In some embodiments, the GAL9 antigen binding molecule increases IFN-γ secretion in activated immune cells by at least 10-15%, 15-20%, 20-25%, 25-30%, 30-35%, 35%-40%, 40%-45%, 45%-50%, 50%-55%, 55%-60%, 60%-65%, 70%-75%, 75%-80%, 80%-85%, 85%-90%, 90%-95%, 95%-100%, 100%-105%, 105%-110%, 110%-115%, or 115%-120%.
In some embodiments, the cytokine is TNF-α. In some embodiments, the GAL9 antigen binding molecule increases TNF-α secretion in activated immune cells by at least 100%, 150%, 200%, 250%, 300%, 350%, 400%, 450%, 500%, 550%, 600%, 650%, 700%, 750%, 800%, 850%, 900%, 950%, 10,00%, 10,500%, 11,000%, 11,500%, 12,000%, 12,500%, 13,000%, 13,500%, 14,000%, 14,500%, 15,000%, 15,500%, 16,000%, 16,500%, 17,000%, 17,500%, 18,000%, 18,500%, 19,000%, 19,500%, 20,000%, 20,500%, 30,000%, 30,500%, 40,000%, 40,500%, 50,000%, 50,500%, 60,000%, 60,500%, 70,000%, 70,500%, 80,000%, 80,500%, 90,000%, or 90,500% as compared to a negative control agent described herein. In some embodiments, the GAL9 antigen binding molecule increases TNF-α secretion in activated immune cells by at least 100%-150%, 150%-200%, 200%-250%, 250%-300%, 300%-350%, 350%-400%, 400%-450%, 500%-550%, 550%-600%, 600%-650%, 650%-700%, 700%-750%, 750%-800%, 800%-850%, 850%-900%, 900%-950%, 950%-10,000%, 10,000%-10,500%, 10,500%-11,000%, 11,000-11,500%, 11,500-12,000%, 12,000%-12,500%, 13,000%-13,500%, 13,500%-14,000%, 14,000%-14,500%, 14,500%-15,000%, 15,000-15,500%, 15,550%-16,000%, 16,000%-16,500%, 17,000%-17,500%, 17,500%-18,000%, 17,500%-18,500%, 18,500%-19,000%, 19,000%-19,500%, 19,500%-20,000%, 20,000%-20,500%, 20,500%-30,000%, 30,000%-30,500%, 30,500%-40,000%, 40,000%-40,500%, 45,500%-50,000%, 50,000%-50,500%, 55,500%-60,000%, 60,000%-60,500%, 70,000%-70,500%, 70,500%-80,000%, 80,000%-80,500%, 85,000%-90,000%, or 90,000%-90,500% as compared to a negative control agent described herein.
In various embodiments, the activated immune cells are T-cells, CD8+ T cells, NK cells, CD4+ T cells, or Dendritic Cells (DC).
In some embodiments, the GAL9 antigen binding molecule increases surface expression of one or more costimulatory molecules on immune cells, e.g., human immune cells. In certain embodiments, the GAL9 antigen binding molecule increases surface expression of the one or more costimulatory molecules in activated immune cells. In particular embodiments, the immune cells are T cells. In specific embodiments, the activated immune cells are CD8+ T cells. In certain embodiments, the activated immune cell is an NK cell. In certain embodiments, the activated immune cell is a dendritic cell.
In some embodiments, the one or more costimulatory molecules is selected from 4-1BB, CD27, CD40L, ICOS, and OX40. In some embodiments, the one or more costimulatory molecules is selected from 4-1BB, CD27, CD40L, and OX40. In some embodiments, the one or more costimulatory molecules is selected from 4-1BB, CD40L, and OX40.
The impact of the GAL9 antigen binding molecule on surface expression of the one or more costimulatory molecules may be determined by any suitable means. For instance, the impact of the GAL9 antigen binding molecule on surface expression of the one or more costimulatory molecules may be determined in vivo, ex vivo, or in vitro.
In some embodiments, the GAL9 antigen binding molecule increases surface expression of the one or more costimulatory molecules in activated immune cells as compared to activated immune cells treated with a control agent. Exemplary control agents are described herein. In particular embodiments, the control agent is an isotype control binding molecule that does not bind GAL9.
In some embodiments, the GAL9 antigen binding molecule increases CD40L surface expression of activated CD8+ T-cells, relative to activated CD8+ T-cells treated with the control agent. In some embodiments, activated CD8+ T-cells treated with the GAL9 antigen binding molecule exhibits at least about a 0.1× increase, 0.2× increase, 0.3× increase, 0.4× increase, 0.5× increase, 0.6× increase, 0.7× increase, 0.8× increase, 0.9× increase, 1× increase, 2× increase, 3× increase, 4× increase, 5× increase, 6× increase, 7× increase, 8× increase, 9× increase, 10× increase, or greater than 10× increase in CD40L surface expression relative to activated CD8+ T-cells treated with the control agent. In some embodiments, activated CD8+ T-cells treated with the GAL9 antigen binding molecule exhibits about a 0.1×-10× increase, a 0.5×-5× increase, a 1×-4× increase, or about a 1.5×-2.5× increase in CD40L surface expression, relative to activated CD8+ T-cells treated with the control agent.
In some embodiments, the GAL9 antigen binding molecule increases OX40 surface expression of activated CD8+ T-cells, relative to activated CD8+ T-cells treated with the control agent. In some embodiments, activated CD8+ T-cells treated with the GAL9 antigen binding molecule exhibits about at least a 0.1× increase, 0.2× increase, 0.3× increase, 0.4× increase, 0.5× increase, 0.6× increase, 0.7× increase, 0.8× increase, 0.9× increase, 1× increase, 2× increase, 3× increase, 4× increase, 5× increase, 6× increase, 7× increase, 8× increase, 9× increase, 10× increase, or greater than 10× increase in OX40 surface expression relative to activated CD8+ T-cells treated with the control agent. In some embodiments, activated CD8+ T-cells treated with the GAL9 antigen binding molecule exhibits about a 0.1×-10× increase, a 0.5×-5× increase, or about a 1.0×-2.0× increase in OX40 surface expression, relative to activated CD8+ T-cells treated with the control agent.
In some embodiments, the GAL9 antigen binding molecule increases 4-1BB surface expression of activated CD8+ T-cells, relative to activated CD8+ T-cells treated with the control agent. In some embodiments, activated CD8+ T-cells treated with the GAL9 antigen binding molecule exhibits about at least a 0.1× increase, 0.2× increase, 0.3× increase, 0.4× increase, 0.5× increase, 0.6× increase, 0.7× increase, 0.8× increase, 0.9× increase, 1× increase, 2× increase, 3× increase, 4× increase, 5× increase, 6× increase, 7× increase, 8× increase, 9× increase, 10× increase, or greater than 10× increase in 4-1BB surface expression relative to activated CD8+ T-cells treated with the control agent. In some embodiments, activated CD8+ T-cells treated with the GAL9 antigen binding molecule exhibits about a 0.1×-10× increase, a 0.2×-2× increase, or about a 0.5×-1× increase in 4-1BB surface expression, relative to activated CD8+ T-cells treated with the control agent.
In some embodiments, the GAL9 antigen binding molecule increases CD27 surface expression of activated CD8+ T-cells, relative to activated CD8+ T-cells treated with the control agent. In some embodiments, activated CD8+ T-cells treated with the GAL9 antigen binding molecule exhibits about at least a 1% increase, 2% increase, 3% increase, 4% increase, 5% increase, 6% increase, 7% increase, 8% increase, 9% increase, 10% increase, 11% increase, 12% increase, 13% increase, 14% increase, 15% increase, 16% increase, 17% increase, 18% increase, 19% increase, 20% increase, 21% increase, 22% increase, 23% increase, 24% increase, 25% increase, 26% increase, 27% increase, 28% increase, 29% increase, 30% increase, 31% increase, 32% increase, 33% increase, 34% increase, 35% increase, 36% increase, 37% increase, 38% increase, 39% increase, 40% increase, 41% increase, 42% increase, 43% increase, 44% increase, 45% increase, 46% increase, 47% increase, 48% increase, 49% increase, 50% increase, 51% increase, 52% increase, 53% increase, 54% increase, 55% increase, 56% increase, 57% increase, 58% increase, 59% increase, 60% increase, 61% increase, 62% increase, 63% increase, 64% increase, 65% increase, 66% increase, 67% increase, 68% increase, 69% increase, 70% increase, 71% increase, 72% increase, 73% increase, 74% increase, 75% increase, 76% increase, 77% increase, 78% increase, 79% increase, 80% increase, 81% increase, 82% increase, 83% increase, 84% increase, 85% increase, 86% increase, 87% increase, 88% increase, 89% increase, 90% increase, 91% increase, 92% increase, 93% increase, 94% increase, 95% increase, 96% increase, 97% increase, 98% increase, 99% increase, or 100% increase in CD27 surface expression, relative to activated CD8+ T-cells treated with the control agent. In some embodiments, activated CD8+ T-cells treated with the GAL9 antigen binding molecule exhibits about at least a 1%-100% increase, a 5%-50% increase, a 10%-40% increase, or about a 20%-30% increase in CD27 surface expression, relative to activated CD8+ T-cells treated with the control agent.
In some embodiments, the GAL9 antigen binding molecule increases ICOS surface expression of activated CD8+ T-cells, relative to activated CD8+ T-cells treated with the control agent. In some embodiments, activated CD8+ T-cells treated with the GAL9 antigen binding molecule exhibits about at least a 1% increase, 2% increase, 3% increase, 4% increase, 5% increase, 6% increase, 7% increase, 8% increase, 9% increase, 10% increase, 11% increase, 12% increase, 13% increase, 14% increase, 15% increase, 16% increase, 17% increase, 18% increase, 19% increase, 20% increase, 21% increase, 22% increase, 23% increase, 24% increase, 25% increase, 26% increase, 27% increase, 28% increase, 29% increase, 30% increase, 31% increase, 32% increase, 33% increase, 34% increase, 35% increase, 36% increase, 37% increase, 38% increase, 39% increase, 40% increase, 41% increase, 42% increase, 43% increase, 44% increase, 45% increase, 46% increase, 47% increase, 48% increase, 49% increase, 50% increase, 51% increase, 52% increase, 53% increase, 54% increase, 55% increase, 56% increase, 57% increase, 58% increase, 59% increase, 60% increase, 61% increase, 62% increase, 63% increase, 64% increase, 65% increase, 66% increase, 67% increase, 68% increase, 69% increase, 70% increase, 71% increase, 72% increase, 73% increase, 74% increase, 75% increase, 76% increase, 77% increase, 78% increase, 79% increase, 80% increase, 81% increase, 82% increase, 83% increase, 84% increase, 85% increase, 86% increase, 87% increase, 88% increase, 89% increase, 90% increase, 91% increase, 92% increase, 93% increase, 94% increase, 95% increase, 96% increase, 97% increase, 98% increase, 99% increase, or 100% increase in ICOS surface expression, relative to activated CD8+ T-cells treated with the control agent. In some embodiments, activated CD8+ T-cells treated with the GAL9 antigen binding molecule exhibits about at least a 1%-100% increase, a 5%-50% increase, a 10%-40% increase, or about a 20%-30% increase in ICOS surface expression, relative to activated CD8+ T-cells treated with the control agent.
In some embodiments, the GAL9 antigen binding molecule increases retention of PD-L1, PD-L2, or both PD-L1 and PD-L2 on the surface of tumor cells. In some embodiments, the increased retention of PD-L1, PD-L2, or both PD-L1 and PD-L2 on the surface of tumor cells is demonstrated by microscopy techniques, e.g., confocal microscopy.
In some embodiments, the GAL9 antigen binding molecule increases PD-L2 expression on the surface of dendritic cells (DCs). In some embodiments, the GAL9 antigen binding molecule decreases PD-L1 expression on the surface of dendritic cells (DCs). In some embodiments, the DCs are activated DCs. Activation of immune cells, including DCs is described herein. Surface expression of proteins, including PD-L1 and PD-L2 on DCs can be assessed by any suitable means. For example, the percentage of DCs that exhibit detectable surface PD-L1 and/or PD-L2 may be measured by, e.g., flow cytometry. In some embodiments, a population of dendritic cells treated with the GAL9 antigen binding molecule exhibits a greater percentage of cells positive for surface PD-L2 as compared to a control population of dendritic cells treated with a control agent. Exemplary control agents are described herein. In some embodiments, the control agent is an isotype antigen binding molecule that does not bind GAL9. In some embodiments, the population of dendritic cells treated with the GAL9 antigen binding molecule exhibits about a 0.1×-100×, a 0.5×-20×, a 1×-10×, or about a 5×-6× increase in the percentage of DCs exhibiting detectable surface PD-L2 expression, relative to a control population of dendritic cells treated with the control agent, e.g., the isotype control antigen binding molecule. In some embodiments, the population of dendritic cells treated with the GAL9 antigen binding molecule exhibits about a 1%-50% decrease, a 5%-30% decrease, or about a 10%-20% decrease in the percentage of DCs exhibiting detectable surface PD-L1 expression, relative to a control population of dendritic cells treated with the control agent, e.g., the isotype control antigen binding molecule.
In some embodiments, the GAL9 antigen binding molecule increases cell surface aggregation of PD-L2 in dendritic cells (DCs). In some embodiments, the DCs are activated DCs. Activation of immune cells, including DCs is described herein. In some embodiments, the increase in cell surface aggregation of PD-L2 is relative to DCs treated with a control agent. Control agents are described herein. In some embodiments, the control agent is an isotype antigen binding molecule that does not bind GAL9. Cell surface aggregation of PD-L2 in DCs may be assessed by any suitable means, e.g., confocal microscopy.
In some embodiments, the GAL9 antigen binding molecule increases IL-12 production by DCs. The DCs may be activated DCs. In some embodiments, the GAL9 antigen binding molecule increases IL-12 production in DCs, relative to DCs treated with a control agent. Exemplary control agents are described herein. In some embodiments, the control agent is an isotype antigen binding molecule that does not bind GAL9. In some embodiments, a population of DCs treated with the GAL9 antigen binding molecule exhibits about a 0.1×-100× increase, a 10×-75× increase, a 20×-40× increase, a 25×-35× increase, or about a 28× increase in the percentage of DCs that are IL-12 positive, as compared to a population of DCs treated with the control agent.
In some embodiments, the GAL9 antigen binding molecule induces clustering of GAL9 and PD-L2 on the surface of the immune cell. In some embodiments, the immune cells can be DCs. In some embodiments, the immune cells can be NK cells.
In some embodiments, the GAL9 antigen binding molecule reduces tumor burden in a subject. The subject can be a mammal. The mammal can be a mouse. In some embodiments, the mammal is a human. In some embodiments, the GAL9 antigen binding molecule prevents growth of a tumor in the subject. The tumor can be, e.g., a colon tumor. In some embodiments, the GAL9 antigen binding molecule reduces tumor growth. In some embodiments, the GAL9 antigen binding molecule reduces tumor growth by about 25%, 50%, or more than 50%. In some embodiments, the tumor is a melanoma tumor. In some embodiments, the reduction in tumor growth is relative to a subject treated with a control agent. Exemplary control agents are described herein. In some embodiments, the control agent is an isotype antigen binding molecule that does not bind GAL9.
The GAL9 binding molecules described herein have variable region domain amino acid sequences of an antibody, including VH and VL antibody domain sequences. VH and VL sequences are described in greater detail below in Sections 6.4.2.1 and 6.4.2.2, respectively.
The VH amino acid sequences in the GAL9 binding molecules described herein are antibody heavy chain variable domain sequences. In a typical antibody arrangement in both nature and in the GAL9 binding molecules described herein, a specific VH amino acid sequence associates with a specific VL amino acid sequence to form an antigen-binding site. In various embodiments, VH amino acid sequences are mammalian sequences, including human sequences, synthesized sequences, or combinations of non-human mammalian, mammalian, and/or synthesized sequences, as described in further detail above in Sections 6.4.2.3 and 6.4.2.4. In various embodiments, VH amino acid sequences are mutated sequences of naturally occurring sequences.
The VL amino acid sequences useful in the GAL9 binding molecules described herein are antibody light chain variable domain sequences. In a typical arrangement in both natural antibodies and the antibody constructs described herein, a specific VL amino acid sequence associates with a specific VH amino acid sequence to form an antigen-binding site. In various embodiments, the VL amino acid sequences are mammalian sequences, including human sequences, synthesized sequences, or combinations of human, non-human mammalian, mammalian, and/or synthesized sequences, as described in further detail below in Sections 6.4.2.3 and 6.4.2.4.
In various embodiments, VL amino acid sequences are mutated sequences of naturally occurring sequences. In certain embodiments, the VL amino acid sequences are lambda (λ) light chain variable domain sequences. In certain embodiments, the VL amino acid sequences are kappa (κ) light chain variable domain sequences. In a preferred embodiment, the VL amino acid sequences are kappa (κ) light chain variable domain sequences.
The VH and VL amino acid sequences comprise highly variable sequences termed “complementarity determining regions” (CDRs), typically three CDRs (CDR1, CDR2, and CDR3). In a variety of embodiments, the CDRs are mammalian sequences, including, but not limited to, mouse, rat, hamster, rabbit, camel, donkey, goat, and human sequences. In a preferred embodiment, the CDRs are human sequences. In various embodiments, the CDRs are naturally occurring sequences. In various embodiments, the CDRs are naturally occurring sequences that have been mutated to alter the binding affinity of the antigen-binding site for a particular antigen or epitope. In certain embodiments, the naturally occurring CDRs have been mutated in an in vivo host through affinity maturation and somatic hypermutation. In certain embodiments, the CDRs have been mutated in vitro through methods including, but not limited to, PCR-mutagenesis and chemical mutagenesis. In various embodiments, the CDRs are synthesized sequences including, but not limited to, CDRs obtained from random sequence CDR libraries and rationally designed CDR libraries. Martin numbering scheme was used to determine the CDR boundaries. See
In various embodiments, CDRs identified as binding an antigen of interest are further mutated (i.e., “affinity matured”) to achieve a desired binding characteristic, such as an increased affinity for the antigen of interest relative to the original CDR. For example, targeted introduction of diversity into the CDRs, including those CDRs identified to bind an antigen of interest, can be introduced using degenerate oligonucleotides. Various randomization schemes can be employed. For example, “soft-randomization” can be used that provides a high bias towards the identity of wild-type sequence at a given amino acid position, such as allowing a given position in CDRs to vary among all twenty amino acids while biasing towards the wild-type sequence by doping the four bases at each codon position at non-equivalent level. As an illustrative example of soft-randomization, if achieving approximately 50% of the wild-type sequence is desired, each base of each codon is kept 70% wild-type and 10% each of other nucleotides and the degenerate oligonucleotides are used to make a focused phage library around the selected CDRs with the resulting phage particles used for phage panning under various stringent selection conditions depending on the need.
The VH and VL amino acid sequences comprise “framework region” (FR) sequences. FRs are generally conserved sequence regions that act as a scaffold for interspersed CDRs (see Section 6.4.2.3), typically in a FR1-CDR1-FR2-CDR2-FR3-CDR3-FR4 arrangement (from N-terminus to C-terminus). In a variety of embodiments, the FRs are mammalian sequences, including, but not limited to mouse, rat, hamster, rabbit, camel, donkey, goat, and human sequences. In a preferred embodiment, the FRs are human sequences. In various embodiments, the FRs are naturally occurring sequences. In various embodiments, the FRs are synthesized sequences including, but not limited, rationally designed sequences.
In a variety of embodiments, the FRs and the CDRs are both from the same naturally occurring variable domain sequence. In a variety of embodiments, the FRs and the CDRs are from different variable domain sequences, wherein the CDRs are grafted onto the FR scaffold with the CDRs providing specificity for a particular antigen. In certain embodiments, the grafted CDRs are all derived from the same naturally occurring variable domain sequence. In certain embodiments, the grafted CDRs are derived from different variable domain sequences. In certain embodiments, the grafted CDRs are synthesized sequences including, but not limited to, CDRs obtained from random sequence CDR libraries and rationally designed CDR libraries. In certain embodiments, the grafted CDRs and the FRs are from the same species. In certain embodiments, the grafted CDRs and the FRs are from different species. In a preferred grafted CDR embodiment, an antibody is “humanized”, wherein the grafted CDRs are non-human mammalian sequences including, but not limited to, mouse, rat, hamster, rabbit, camel, donkey, and goat sequences, and the FRs are human sequences. Humanized antibodies are discussed in more detail in U.S. Pat. No. 6,407,213, the entirety of which is hereby incorporated by reference for all it teaches. In various embodiments, portions or specific sequences of FRs from one species are used to replace portions or specific sequences of another species' FRs.
In various embodiment, the GAL9 binding molecule comprises a particular VH CDR3 (CDR-H3) sequence and a particular VL CDR3 (CDR-L3) sequence.
In some embodiments, the GAL9 binding molecule comprises the CDR-H3 and the CDR-L3 from any one of the ABS clones selected from P9-02B, P9-04, P9-05, P9-08, P9-09, P9-10, P9-15, P9-16, P9-18, P9-19, P9-20, P9-21, P9-22, P9-27, P9-28, P9-31, P9-32, P9-36, P9-39, P9-49, P9-54, and P9-58. VH CDR amino acid sequences of the ABS clones are disclosed in Table 3. VL CDR amino acid sequences of the ABS clones are disclosed in Table 4. For clarity, each GAL9 ABS clone is assigned a unique ABS clone number which is used throughout this disclosure.
In one currently preferred embodiment, the GAL9 binding molecule comprises the CDR-H3 and CDR-L3 of ABS clone P9-28.
In some embodiments, the GAL9 binding molecule comprises all three VH CDRs from one of the ABS clones selected from P9-02B, P9-04, P9-05, P9-08, P9-09, P9-10, P9-15, P9-16, P9-18, P9-19, P9-20, P9-21, P9-22, P9-27, P9-28, P9-31, P9-32, P9-36, P9-39, P9-49, P9-54, and P9-58. In one currently preferred embodiment, the GAL9 binding molecule comprises all three VH CDRs from ABS clone P9-28.
In some embodiments, the GAL9 binding molecule comprises all three VL CDRs from one of the ABS clones selected from P9-02B, P9-04, P9-05, P9-08, P9-09, P9-10, P9-15, P9-16, P9-18, P9-19, P9-20, P9-21, P9-22, P9-27, P9-28, P9-31, P9-32, P9-36, P9-39, P9-49, P9-54, and P9-58. In one currently preferred embodiment, the GAL9 binding molecule comprises all three VL CDRs from ABS clone P9-28.
In some embodiments, the GAL9 binding molecule comprises all six CDRs from any one of the ABS clones selected from P9-02B, P9-04, P9-05, P9-08, P9-09, P9-10, P9-15, P9-16, P9-18, P9-19, P9-20, P9-21, P9-22, P9-27, P9-28, P9-31, P9-32, P9-36, P9-39, P9-49, P9-54, and P9-58. In one currently preferred embodiment, the GAL9 binding molecule comprises all six CDRs from ABS clone P9-28.
In some embodiments, the GAL9 binding molecule comprises a VH amino acid sequence, a VL amino acid sequence, or a VH and VL amino acid sequence from any one of the ABS clones selected from P9-02B, P9-04, P9-05, P9-08, P9-09, P9-10, P9-15, P9-16, P9-18, P9-19, P9-20, P9-21, P9-22, P9-27, P9-28, P9-31, P9-32, P9-36, P9-39, P9-49, P9-54, and P9-58. Full immunoglobulin heavy chain and immunoglobulin light chain sequences, as well as VH and VL amino acid sequences, are provided in Table 6. In certain currently preferred embodiments, the GAL9 binding molecule comprises a VH amino acid sequence, a VL amino acid sequence, or a VH and VL amino acid sequence from ABS clone P9-28.
In some embodiments, the GAL9 binding molecule comprises the full IgG heavy chain sequence and the full IgG light chain sequence from any one of the ABS clones selected from P9-02B, P9-04, P9-05, P9-08, P9-09, P9-10, P9-15, P9-16, P9-18, P9-19, P9-20, P9-21, P9-22, P9-27, P9-28, P9-31, P9-32, P9-36, P9-39, P9-49, P9-54, and P9-58. In one currently preferred embodiment, the GAL9 binding molecule comprises the full IgG heavy chain sequence and the full IgG light chain sequence from ABS clone P9-28.
In the GAL9 binding molecules, the GAL9 binding molecule can have a constant region domain sequence. Constant region domain amino acid sequences, as described herein, are sequences of a constant region domain of an antibody. Constant regions can refer to CH1, CH2, CH3, CH4, or CL constant domain.
In a variety of embodiments, the constant region sequences are mammalian sequences, including, but not limited to, mouse, rat, hamster, rabbit, camel, donkey, goat, and human sequences. In a preferred embodiment, the constant region sequences are human sequences. In certain embodiments, the constant region sequences are from an antibody light chain. In particular embodiments, the constant region sequences are from a lambda or kappa light chain. In certain embodiments, the constant region sequences are from an antibody heavy chain. In particular embodiments, the constant region sequences are an antibody heavy chain sequence that is an IgA1, IgA2, IgD, IgE, IgG1, IgG2, IgG3, IgG4, or IgM isotype. In a specific embodiment, the constant region sequences are from an IgG isotype. In a preferred embodiment, the constant region sequences are from an IgG1 isotype.
Exemplary constant regions and modifications thereof are described in WO2018075692, which is hereby incorporated by reference in its entirety.
CH1 amino acid sequences, as described herein, are sequences of the second domain of an antibody heavy chain, with reference from the N-terminus to C-terminus of a native antibody heavy chain architecture. In certain embodiments, the CH1 sequences are endogenous sequences. In a variety of embodiments, the CH1 sequences are mammalian sequences, including, but not limited to mouse, rat, hamster, rabbit, camel, donkey, goat, and human sequences. In a preferred embodiment, the CH1 sequences are human sequences. In certain embodiments, the CH1 sequences are from an IgA1, IgA2, IgD, IgE, IgG1, IgG2, IgG3, IgG4, or IgM isotype. In a preferred embodiment, the CH1 sequences are from an IgG1 isotype. In preferred embodiments, the CH1 sequence is UniProt accession number P01857 amino acids 1-98.
The CL amino acid sequences useful in the GAL9 binding molecules described herein are antibody light chain constant domain sequences, with reference to a native antibody light chain architecture. In certain embodiments, the CL sequences are endogenous sequences. In a variety of embodiments, the CL sequences are mammalian sequences, including, but not limited to mouse, rat, hamster, rabbit, camel, donkey, goat, and human sequences. In a preferred embodiment, CL sequences are human sequences.
In certain embodiments, the CL amino acid sequences are lambda (λ) light chain constant domain sequences. In particular embodiments, the CL amino acid sequences are human lambda light chain constant domain sequences. In preferred embodiments, the lambda (λ) light chain sequence is UniProt accession number P0CG04.
In certain embodiments, the CL amino acid sequences are kappa (κ) light chain constant domain sequences. In a preferred embodiment, the CL amino acid sequences are human kappa (κ) light chain constant domain sequences. In a preferred embodiment, the kappa light chain sequence is UniProt accession number P01834.
In certain embodiments, the CH1 sequence and the CL sequences are both endogenous sequences. In certain embodiments, the CH1 sequence and the CL sequences separately comprise respectively orthogonal modifications in endogenous CH1 and CL sequences, as discussed below in greater detail in Section 6.4.4.1. CH1 and CL sequences can also be portions thereof, either of an endogenous or modified sequence, such that a domain having the CH1 sequence, or portion thereof, can associate with a domain having the CL sequence, or portion thereof.
In certain embodiments, the CH1 sequence and the CL sequences separately comprise respectively orthogonal modifications in endogenous CH1 and CL sequences. Orthogonal mutations, in general, are described in more detail below in Sections 6.4.6.1-6.4.6.3.
In particular embodiments, the orthogonal modifications in endogenous CH1 and CL sequences are an engineered disulfide bridge selected from engineered cysteines at position 138 of the CH1 sequence and position 116 of the CL sequence, at position 128 of the CH1 sequence and position 119 of the CL sequence, or at position 129 of the CH1 sequence and position 210 of the CL sequence, as numbered and discussed in more detail in U.S. Pat. Nos. 8,053,562 and 9,527,927, each incorporated herein by reference in its entirety. In a preferred embodiment, the engineered cysteines are at position 128 of the CH1 sequence and position 118 of the CL Kappa sequence, as numbered by the Eu index.
In a series of preferred embodiments, the mutations that provide non-endogenous cysteine amino acids are a F118C mutation in the CL sequence with a corresponding A141C in the CH1 sequence, or a F118C mutation in the CL sequence with a corresponding L128C in the CH1 sequence, or a S162C mutations in the CL sequence with a corresponding P171C mutation in the CH1 sequence, as numbered by the Eu index.
In a variety of embodiments, the orthogonal mutations in the CL sequence and the CH1 sequence are charge-pair mutations. In specific embodiments the charge-pair mutations are a F118S, F118A or F118V mutation in the CL sequence with a corresponding A141L in the CH1 sequence, or a T129R mutation in the CL sequence with a corresponding K147D in the CH1 sequence, as numbered by the Eu index and described in greater detail in Bonisch et al. (Protein Engineering, Design & Selection, 2017, pp. 1-12), herein incorporated by reference for all that it teaches. In a series of preferred embodiments, the charge-pair mutations are a N138K mutation in the CL sequence with a corresponding G166D in the CH1 sequence, or a N138D mutation in the CL sequence with a corresponding G166K in the CH1 sequence, as numbered by the Eu index.
In the GAL9 binding molecules described herein, the GAL9 binding molecules can have a CH2 amino acid sequence. CH2 amino acid sequences, as described herein, are CH2 amino acid sequences of the third domain of an antibody heavy chain, with reference from the N-terminus to C-terminus of a native antibody heavy chain architecture. In a variety of embodiments, the CH2 sequences are mammalian sequences, including but not limited to mouse, rat, hamster, rabbit, camel, donkey, goat, and human sequences. In a preferred embodiment, the CH2 sequences are human sequences. In certain embodiments, the CH2 sequences are from an IgA1, IgA2, IgD, IgE, IgG1, IgG2, IgG3, IgG4, or IgM isotype. In a preferred embodiment, the CH2 sequences are from an IgG1 isotype.
In certain embodiments, the CH2 sequences are endogenous sequences. In particular embodiments, the sequence is UniProt accession number P01857 amino acids 111-223.
In a series of embodiments, a GAL9 binding molecule has more than one paired set of CH2 domains that have CH2 sequences, wherein a first set has CH2 amino acid sequences from a first isotype and one or more orthologous sets of CH2 amino acid sequences from another isotype. The orthologous CH2 amino acid sequences, as described herein, are able to interact with CH2 amino acid sequences from a shared isotype, but not significantly interact with the CH2 amino acid sequences from another isotype present in the GAL9 binding molecule. In particular embodiments, all sets of CH2 amino acid sequences are from the same species. In preferred embodiments, all sets of CH2 amino acid sequences are human CH2 amino acid sequences. In other embodiments, the sets of CH2 amino acid sequences are from different species. In particular embodiments, the first set of CH2 amino acid sequences is from the same isotype as the other non-CH2 domains in the GAL9 binding molecule. In a specific embodiment, the first set has CH2 amino acid sequences from an IgG isotype and the one or more orthologous sets have CH2 amino acid sequences from an IgM or IgE isotype. In certain embodiments, one or more of the sets of CH2 amino acid sequences are endogenous CH2 sequences. In other embodiments, one or more of the sets of CH2 amino acid sequences are endogenous CH2 sequences that have one or more mutations. In particular embodiments, the one or more mutations are orthogonal knob-hole mutations, orthogonal charge-pair mutations, or orthogonal hydrophobic mutations. Orthologous CH2 amino acid sequences useful for the GAL9 binding molecules are described in more detail in international PCT applications WO2017/011342 and WO2017/106462, herein incorporated by reference in their entirety.
CH3 amino acid sequences, as described herein, are sequences of the C-terminal domain of an antibody heavy chain, with reference from the N-terminus to C-terminus of a native antibody heavy chain architecture.
In a variety of embodiments, the CH3 sequences are mammalian sequences, including, but not limited to, mouse, rat, hamster, rabbit, camel, donkey, goat, and human sequences. In a preferred embodiment, the CH3 sequences are human sequences. In certain embodiments, the CH3 sequences are from an IgA1, IgA2, IgD, IgE, IgM, IgG1, IgG2, IgG3, IgG4 isotype or CH4 sequences from an IgE or IgM isotype. In a specific embodiment, the CH3 sequences are from an IgG isotype. In a preferred embodiment, the CH3 sequences are from an IgG1 isotype.
In certain embodiments, the CH3 sequences are endogenous sequences. In particular embodiments, the CH3 sequence is UniProt accession number P01857 amino acids 224-330. In various embodiments, a CH3 sequence is a segment of an endogenous CH3 sequence. In particular embodiments, a CH3 sequence has an endogenous CH3 sequence that lacks the N-terminal amino acids G224 and Q225. In particular embodiments, a CH3 sequence has an endogenous CH3 sequence that lacks the C-terminal amino acids P328, G329, and K330. In particular embodiments, a CH3 sequence has an endogenous CH3 sequence that lacks both the N-terminal amino acids G224 and Q225 and the C-terminal amino acids P328, G329, and K330. In preferred embodiments, a GAL9 binding molecule has multiple domains that have CH3 sequences, wherein a CH3 sequence can refer to both a full endogenous CH3 sequence as well as a CH3 sequence that lacks N-terminal amino acids, C-terminal amino acids, or both.
In certain embodiments, the CH3 sequences are endogenous sequences that have one or more mutations. In particular embodiments, the mutations are one or more orthogonal mutations that are introduced into an endogenous CH3 sequence to guide specific pairing of specific CH3 sequences, as described in more detail below in Sections 6.4.6.1-6.4.6.3.
In certain embodiments, the CH3 sequences are engineered to reduce immunogenicity of the antibody by replacing specific amino acids of one allotype with those of another allotype and referred to herein as isoallotype mutations, as described in more detail in Stickler et al. (Genes Immun. 2011 April; 12(3): 213-221), which is herein incorporated by reference for all that it teaches. In particular embodiments, specific amino acids of the G1 ml allotype are replaced. In a preferred embodiment, isoallotype mutations D356E and L358M are made in the CH3 sequence.
In some embodiments, an IgG1 CH3 amino acid sequence comprises the following mutational changes: P343V; Y349C; and a tripeptide insertion, 445P, 446G, 447K. In other preferred embodiments, domain B has a human IgG1 CH3 sequence with the following mutational changes: T366K; and a tripeptide insertion, 445K, 446S, 447C. In still other preferred embodiments, domain B has a human IgG1 CH3 sequence with the following mutational changes: Y349C and a tripeptide insertion, 445P, 446G, 447K.
In some embodiments, an IgG1 CH3 amino acid sequence comprises a 447C mutation incorporated into an otherwise endogenous CH3 sequence.
In some embodiments, a VL or VH amino acid sequence and a cognate VL or VH amino acid sequence are associated and form a first antigen binding site (ABS). The antigen binding site (ABS) is capable of specifically binding an epitope of an antigen. Antigen binding by an ABS is described in greater detail below in Section 6.4.5.1.
In alternative embodiments, e.g., wherein the GAL9 binding molecule is a single domain antibody, a VH or VL amino acid sequence forms the first ABS.
In some embodiments, the GAL9 antigen binding molecule comprises a second ABS. In some embodiments, the second ABS is specific for the same GAL9 antigen as the first ABS. In some embodiments, the second ABS specifically binds the same epitope of the same GAL9 antigen as the first ABS. In some embodiments, the second ABS is identical to the first ABS.
In some embodiments, the second ABS is specific for a different epitope of the first GAL9 antigen. For example if the first ABS comprises CDRs or variable domains from any one of the ABS clones selected from P9-02B, P9-04, P9-05, P9-08, P9-09, P9-10, P9-15, P9-16, P9-18, P9-19, P9-20, P9-21, P9-22, P9-27, P9-28, P9-31, P9-32, P9-36, P9-39, P9-49, P9-54, and P9-58, the second ABS may comprise CDRs or variable domains from another ABS clone selected from P9-02B, P9-04, P9-05, P9-08, P9-09, P9-10, P9-15, P9-16, P9-18, P9-19, P9-20, P9-21, P9-22, P9-27, P9-28, P9-31, P9-32, P9-36, P9-39, P9-49, P9-54, and P9-58.
In some embodiments, the GAL9 antigen binding molecule is multispecific, e.g., the second ABS of the GAL9 antigen binding molecule specifically binds an antigen that is different than the GAL9 antigen specifically bound by the first ABS.
An ABS, and the GAL9 binding molecule comprising such ABS, is said to “recognize” the epitope (or more generally, the antigen) to which the ABS specifically binds, and the epitope (or more generally, the antigen) is said to be the “recognition specificity” or “binding specificity” of the ABS.
The ABS is said to bind to its specific antigen or epitope with a particular affinity. As described herein, “affinity” refers to the strength of interaction of non-covalent intermolecular forces between one molecule and another. The affinity, i.e. the strength of the interaction, can be expressed as a dissociation equilibrium constant (KD), wherein a lower KD value refers to a stronger interaction between molecules. KD values of antibody constructs are measured by methods well known in the art including, but not limited to, bio-layer interferometry (e.g., Octet/FORTEBIO®), surface plasmon resonance (SPR) technology (e.g., Biacore®), and cell binding assays. For purposes herein, affinities are dissociation equilibrium constants measured by bio-layer interferometry using Octet/FORTEBIO®.
“Specific binding,” as used herein, refers to an affinity between an ABS and its cognate antigen or epitope in which the KD value is below 10−6M, 10−7M, 10−8M, 10−9M, or 10−10M.
The number of ABSs in a GAL9 binding molecule as described herein defines the “valency” of the GAL9 binding molecule. A GAL9 binding molecule having a single ABS is “monovalent”. A GAL9 binding molecule having a plurality of ABSs is said to be “multivalent”. A multivalent GAL9 binding molecule having two ABSs is “bivalent.” A multivalent GAL9 binding molecule having three ABSs is “trivalent.” A multivalent GAL9 binding molecule having four ABSs is “tetravalent.”
In various multivalent embodiments, all of the plurality of ABSs have the same recognition specificity. Such a GAL9 binding molecule is a “monospecific” “multivalent” binding construct. In other multivalent embodiments, at least two of the plurality of ABSs have different recognition specificities. Such GAL9 binding molecules are multivalent and “multispecific”. In multivalent embodiments in which the ABSs collectively have two recognition specificities, the GAL9 binding molecule is “bispecific.” In multivalent embodiments in which the ABSs collectively have three recognition specificities, the GAL9 binding molecule is “trispecific.”
In multivalent embodiments in which the ABSs collectively have a plurality of recognition specificities for different epitopes present on the same antigen, the GAL9 binding molecule is “multiparatopic.” Multivalent embodiments in which the ABSs collectively recognize two epitopes on the same antigen are “biparatopic.”
In various multivalent embodiments, multivalency of the GAL9 binding molecule improves the avidity of the GAL9 binding molecule for a specific target. As described herein, “avidity” refers to the overall strength of interaction between two or more molecules, e.g. a multivalent GAL9 binding molecule for a specific target, wherein the avidity is the cumulative strength of interaction provided by the affinities of multiple ABSs. Avidity can be measured by the same methods as those used to determine affinity, as described above. In certain embodiments, the avidity of a GAL9 binding molecule for a specific target is such that the interaction is a specific binding interaction, wherein the avidity between two molecules has a KD value below 10−6M, 10−7M, 10−8M, 10−9M, or 10−10M. In certain embodiments, the avidity of a GAL9 binding molecule for a specific target has a KD value such that the interaction is a specific binding interaction, wherein the one or more affinities of individual ABSs do not have has a KD value that qualifies as specifically binding their respective antigens or epitopes on their own. In certain embodiments, the avidity is the cumulative strength of interaction provided by the affinities of multiple ABSs for separate antigens on a shared specific target or complex, such as separate antigens found on an individual cell. In certain embodiments, the avidity is the cumulative strength of interaction provided by the affinities of multiple ABSs for separate epitopes on a shared individual antigen.
In the GAL9 binding molecules described herein, a GAL9 binding molecule can have constant region domains comprising orthogonal modifications. Constant region domain amino acid sequences are described in greater detail above in Section 6.4.4.
“Orthogonal modifications” or synonymously “orthogonal mutations” as described herein are one or more engineered mutations in an amino acid sequence of an antibody domain that increase the affinity of binding of a first domain having orthogonal modification for a second domain having a complementary orthogonal modification. In certain embodiments, the orthogonal modifications decrease the affinity of a domain having the orthogonal modifications for a domain lacking the complementary orthogonal modifications. In certain embodiments, orthogonal modifications are mutations in an endogenous antibody domain sequence. In a variety of embodiments, orthogonal modifications are modifications of the N-terminus or C-terminus of an endogenous antibody domain sequence including, but not limited to, amino acid additions or deletions. In particular embodiments, orthogonal modifications include, but are not limited to, engineered disulfide bridges, knob-in-hole mutations, and charge-pair mutations, as described in greater detail below in Sections 6.4.6.1-6.4.6.3. In particular embodiments, orthogonal modifications include a combination of orthogonal modifications selected from, but not limited to, engineered disulfide bridges, knob-in-hole mutations, and charge-pair mutations. In particular embodiments, the orthogonal modifications can be combined with amino acid substitutions that reduce immunogenicity, such as isoallotype mutations, as described in greater detail above in Section 6.4.4.4.
In a variety of embodiments, the orthogonal modifications comprise mutations that generate engineered disulfide bridges between a first and a second domain. As described herein, “engineered disulfide bridges” are mutations that provide non-endogenous cysteine amino acids in two or more domains such that a non-native disulfide bond forms when the two or more domains associate. Engineered disulfide bridges are described in greater detail in Merchant et al. (Nature Biotech (1998) 16:677-681), the entirety of which is hereby incorporated by reference for all it teaches. In certain embodiments, engineered disulfide bridges improve orthogonal association between specific domains. In a particular embodiment, the mutations that generate engineered disulfide bridges are a K392C mutation in one of a first or second CH3 domains, and a D399C in the other CH3 domain. In a preferred embodiment, the mutations that generate engineered disulfide bridges are a S354C mutation in one of a first or second CH3 domains, and a Y349C in the other CH3 domain. In another preferred embodiment, the mutations that generate engineered disulfide bridges are a 447C mutation in both the first and second CH3 domains that are provided by extension of the C-terminus of a CH3 domain incorporating a KSC tripeptide sequence.
In a variety of embodiments, orthogonal modifications comprise knob-hole (synonymously, knob-in-hole) mutations. As described herein, knob-hole mutations are mutations that change the steric features of a first domain's surface such that the first domain will preferentially associate with a second domain having complementary steric mutations relative to association with domains without the complementary steric mutations. Knob-hole mutations are described in greater detail in U.S. Pat. Nos. 5,821,333 and 8,216,805, each of which is incorporated herein in its entirety. In various embodiments, knob-hole mutations are combined with engineered disulfide bridges, as described in greater detail in Merchant et al. (Nature Biotech (1998) 16:677-681), incorporated herein by reference in its entirety. In various embodiments, knob-hole mutations, isoallotype mutations, and engineered disulfide mutations are combined.
In certain embodiments, the knob-in-hole mutations are a T366Y mutation in a first domain, and a Y407T mutation in a second domain. In certain embodiments, the knob-in-hole mutations are a F405A in a first domain, and a T394W in a second domain. In certain embodiments, the knob-in-hole mutations are a T366Y mutation and a F405A in a first domain, and a T394W and a Y407T in a second domain. In certain embodiments, the knob-in-hole mutations are a T366W mutation in a first domain, and a Y407A in a second domain. In certain embodiments, the combined knob-in-hole mutations and engineered disulfide mutations are a S354C and T366W mutations in a first domain, and a Y349C, T366S, L368A, and a Y407V mutation in a second domain. In a preferred embodiment, the combined knob-in-hole mutations, isoallotype mutations, and engineered disulfide mutations are a S354C and T366W mutations in a first domain, and a Y349C, D356E, L358M, T366S, L368A, and a Y407V mutation in a second domain.
In a variety of embodiments, orthogonal modifications are charge-pair mutations. As used herein, charge-pair mutations are mutations that affect the charge of an amino acid in a domain's surface such that the domain will preferentially associate with a second domain having complementary charge-pair mutations relative to association with domains without the complementary charge-pair mutations. In certain embodiments, charge-pair mutations improve orthogonal association between specific domains. Charge-pair mutations are described in greater detail in U.S. Pat. Nos. 8,592,562, 9,248,182, and 9,358,286, each of which is incorporated by reference herein for all they teach. In certain embodiments, charge-pair mutations improve stability between specific domains. In a preferred embodiment, the charge-pair mutations are a T366K mutation in a first domain, and a L351D mutation in the other domain.
In specific embodiments, the orthogonal mutations are charge-pair mutations at the VH/VL interface. In preferred embodiments, the charge-pair mutations at the VH/VL interface are a Q39E in VH with a corresponding Q38K in VL, or a Q39K in VH with a corresponding Q38E in VL, as described in greater detail in Igawa et al. (Protein Eng. Des. Sel., 2010, vol. 23, 667-677), herein incorporated by reference for all it teaches.
In another series of embodiments, the GAL9 binding molecules have three antigen binding sites and are therefore termed “trivalent.” In a variety of embodiments, the GAL9 binding molecules have 4 antigen binding sites and are therefore termed “tetravalent.”
The antigen binding sites described herein, including specific CDR subsets, can be formatted into any binding molecule architecture including, but not limited to, full-length antibodies, Fab fragments, Fvs, scFvs, tandem scFvs, Diabodies, scDiabodies, DARTs, tandAbs, minibodies, camelid VHH, and other antibody fragments or formats known to those skilled in the art. Exemplary antibody and antibody fragment formats are described in detail in Brinkmann et al. (MABS, 2017, Vol. 9, No. 2, 182-212), herein incorporated by reference for all that it teaches. The antigen binding sites described herein, including specific CDR subsets, can also be formatted into a “B-body” format, as described in more detail in US pre-grant publication no. US 2018/0118811 and International Application Pub. No. WO 2018/075692, each of which is herein incorporated by reference in their entireties.
In a further series of embodiments, the GAL9 binding molecule has additional modifications.
In various embodiments, the GAL9 binding molecule is conjugated to a therapeutic agent (i.e. drug) to form a GAL9 binding molecule-drug conjugate. Therapeutic agents include, but are not limited to, chemotherapeutic agents, imaging agents (e.g. radioisotopes), immune modulators (e.g. cytokines, chemokines, or checkpoint inhibitors), and toxins (e.g. cytotoxic agents). In certain embodiments, the therapeutic agents are attached to the GAL9 binding molecule through a linker peptide, as discussed in more detail below in Section 6.6.3.
Methods of preparing antibody-drug conjugates (ADCs) that can be adapted to conjugate drugs to the GAL9 binding molecules disclosed herein are described, e.g., in U.S. Pat. No. 8,624,003 (pot method), U.S. Pat. No. 8,163,888 (one-step), U.S. Pat. No. 5,208,020 (two-step method), U.S. Pat. Nos. 8,337,856, 5,773,001, 7,829,531, 5,208,020, 7,745,394, WO 2017/136623, WO 2017/015502, WO 2017/015496, WO 2017/015495, WO 2004/010957, WO 2005/077090, WO 2005/082023, WO 2006/065533, WO 2007/030642, WO 2007/103288, WO 2013/173337, WO 2015/057699, WO 2015/095755, WO 2015/123679, WO 2015/157286, WO 2017/165851, WO 2009/073445, WO 2010/068759, WO 2010/138719, WO 2012/171020, WO 2014/008375, WO 2014/093394, WO 2014/093640, WO 2014/160360, WO 2015/054659, WO 2015/195925, WO 2017/160754, Storz (MAbs. 2015 November-December; 7(6): 989-1009), Lambert et al. (Adv Ther, 2017 34: 1015), Diamantis et al. (British Journal of Cancer, 2016, 114, 362-367), Carrico et al. (Nat Chem Biol, 2007. 3: 321-2), We et al. (Proc Natl Acad Sci USA, 2009. 106: 3000-5), Rabuka et al. (Curr Opin Chem Biol., 2011 14: 790-6), Hudak et al. (Angew Chem Int Ed Engl., 2012: 4161-5), Rabuka et al. (Nat Protoc., 2012 7:1052-67), Agarwal et al. (Proc Natl Acad Sci USA., 2013, 110: 46-51), Agarwal et al. (Bioconjugate Chem., 2013, 24: 846-851), Barfield et al. (Drug Dev. and D., 2014, 14:34-41), Drake et al. (Bioconjugate Chem., 2014, 25:1331-41), Liang et al. (J Am Chem Soc., 2014, 136:10850-3), Drake et al. (Curr Opin Chem Biol., 2015, 28:174-80), and York et al. (BMC Biotechnology, 2016, 16(1):23), each of which is hereby incorporated by reference in its entirety for all that it teaches.
In various embodiments, the GAL9 binding molecule has modifications that comprise one or more additional binding moieties. In certain embodiments the binding moieties are antibody fragments or antibody formats including, but not limited to, full-length antibodies, Fab fragments, Fvs, scFvs, tandem scFvs, Diabodies, scDiabodies, DARTs, tandAbs, minibodies, camelid VHH, and other antibody fragments or formats known to those skilled in the art. Exemplary antibody and antibody fragment formats are described in detail in Brinkmann et al. (MABS, 2017, Vol. 9, No. 2, 182-212), herein incorporated by reference for all that it teaches.
In particular embodiments, the one or more additional binding moieties are attached to the C-terminus of the first or third polypeptide chain. In particular embodiments, the one or more additional binding moieties are attached to the C-terminus of both the first and third polypeptide chain. In particular embodiments, the one or more additional binding moieties are attached to the C-terminus of both the first and third polypeptide chains. In certain embodiments, individual portions of the one or more additional binding moieties are separately attached to the C-terminus of the first and third polypeptide chains such that the portions form the functional binding moiety.
In particular embodiments, the one or more additional binding moieties are attached to the N-terminus of any of the polypeptide chains (e.g. the first, second, third, fourth, fifth, or sixth polypeptide chains). In certain embodiments, individual portions of the additional binding moieties are separately attached to the N-terminus of different polypeptide chains such that the portions form the functional binding moiety.
In certain embodiments, the one or more additional binding moieties are specific for a different antigen or epitope of the ABSs within the GAL9 binding molecule. In certain embodiments, the one or more additional binding moieties are specific for the same antigen or epitope of the ABSs within the GAL9 binding molecule. In certain embodiments, wherein the modification is two or more additional binding moieties, the additional binding moieties are specific for the same antigen or epitope. In certain embodiments, wherein the modification is two or more additional binding moieties, the additional binding moieties are specific for different antigens or epitopes.
In certain embodiments, the one or more additional binding moieties are attached to the GAL9 binding molecule using in vitro methods including, but not limited to, reactive chemistry and affinity tagging systems, as discussed in more detail below in Section 6.6.3. In certain embodiments, the one or more additional binding moieties are attached to the GAL9 binding molecule through Fc-mediated binding (e.g. Protein A/G). In certain embodiments, the one or more additional binding moieties are attached to the GAL9 binding molecule using recombinant DNA techniques, such as encoding the nucleotide sequence of the fusion product between the GAL9 binding molecule and the additional binding moieties on the same expression vector (e.g., plasmid).
In various embodiments, the GAL9 binding molecule has modifications that comprise functional groups or chemically reactive groups that can be used in downstream processes, such as linking to additional moieties (e.g., drug conjugates and additional binding moieties, as discussed in more detail above in Sections 6.6.1. and 6.6.2.) and downstream purification processes.
In certain embodiments, the modifications are chemically reactive groups including, but not limited to, reactive thiols (e.g. maleimide based reactive groups), reactive amines (e.g., N-hydroxysuccinimide based reactive groups), “click chemistry” groups (e.g. reactive alkyne groups), and aldehydes bearing formylglycine (FGly). In certain embodiments, the modifications are functional groups including, but not limited to, affinity peptide sequences (e.g., HA, HIS, FLAG, GST, MBP, and Strep systems etc.). In certain embodiments, the functional groups or chemically reactive groups have a cleavable peptide sequence. In particular embodiments, the cleavable peptide is cleaved by means including, but not limited to, photocleavage, chemical cleavage, protease cleavage, reducing conditions, and pH conditions. In particular embodiments, protease cleavage is carried out by intracellular proteases. In particular embodiments, protease cleavage is carried out by extracellular or membrane associated proteases. ADC therapies adopting protease cleavage are described in more detail in Choi et al. (Theranostics, 2012; 2(2): 156-178), the entirety of which is hereby incorporated by reference for all it teaches.
In certain embodiments, the GAL9 binding molecule has one or more engineered mutations in an amino acid sequence of an antibody domain that reduce the effector functions naturally associated with antibody binding. Effector functions include, but are not limited to, cellular functions that result from an Fc receptor binding to an Fc portion of an antibody, such as antibody-dependent cellular cytotoxicity (ADCC, also referred to as antibody-dependent cell-mediated cytotoxicity), complement fixation (e.g. C1q binding), antibody dependent cellular-mediated phagocytosis (ADCP), and opsonization. Exemplary engineered mutations that reduce the effector functions are described in more detail in U.S. Pub. No. 2017/0137530, Armour, et al. (Eur. J. Immunol. 29(8) (1999) 2613-2624), Shields, et al. (J. Biol. Chem. 276(9) (2001) 6591-6604), and Oganesyan, et al. (Acta Cristallographica D64 (2008) 700-704), each of which is herein incorporated by reference in its entirety.
A method of purifying a GAL9 binding molecule is provided herein. Purification steps include, but are not limited to, purifying the GAL9 binding molecules based on protein characteristics, such as size (e.g., size exclusion chromatography), charge (e.g., ion exchange chromatography), or hydrophobicity (e.g., hydrophobicity interaction chromatography). In one embodiment, cation exchange chromatograph is performed. Other purification methods known to those skilled in the art can be performed including, but not limited to, use of Protein A, Protein G, or Protein A/G reagents. Multiple iterations of a single purification method can be performed. A combination of purification methods can be performed.
In the embodiments of the present invention, at least four distinct polypeptide chains associate together to form a complete complex, i.e., the GAL9 binding molecule. However, incomplete complexes can also form that do not contain the at least four distinct polypeptide chains. For example, incomplete complexes may form that only have one, two, or three of the polypeptide chains. In other examples, an incomplete complex may contain more than three polypeptide chains, but does not contain the at least four distinct polypeptide chains, e.g., the incomplete complex inappropriately associates with more than one copy of a distinct polypeptide chain. The method of the invention purifies the complex, i.e., the completely assembled GAL9 binding molecule, from incomplete complexes.
Methods to assess the efficacy and efficiency of the purification steps are well known to those skilled in the art and include, but are not limited to, SDS-PAGE analysis, ion exchange chromatography, size exclusion chromatography, and mass spectrometry. Purity can also be assessed according to a variety of criteria. Examples of criterion include, but are not limited to: 1) assessing the percentage of the total protein in an eluate that is provided by the completely assembled GAL9 binding molecule, 2) assessing the fold enrichment or percent increase of the method for purifying the desired products, e.g., comparing the total protein provided by the completely assembled GAL9 binding molecule in the eluate to that in a starting sample, 3) assessing the percentage of the total protein or the percent decrease of undesired products, e.g., the incomplete complexes described above, including determining the percent or the percent decrease of specific undesired products (e.g., unassociated single polypeptide chains, dimers of any combination of the polypeptide chains, or trimers of any combination of the polypeptide chains). Purity can be assessed after any combination of methods described herein.
The GAL9 binding molecules described herein can readily be manufactured by expression using standard cell free translation, transient transfection, and stable transfection approaches currently used for antibody manufacture. In specific embodiments, Expi293 cells (ThermoFisher) can be used for production of the GAL9 binding molecules using protocols and reagents from ThermoFisher, such as ExpiFectamine, or other reagents known to those skilled in the art, such as polyethylenimine as described in detail in Fang et al. (Biological Procedures Online, 2017, 19:11), herein incorporated by reference for all it teaches.
The expressed proteins can be readily separated from undesired proteins and protein complexes using various purification strategies including, but not limited to, use of Protein A, Protein G, or Protein A/G reagents. Further purification can be affected using ion exchange chromatography as is routinely used in the art.
In another aspect, pharmaceutical compositions are provided that comprise a GAL9 binding molecule as described herein and a pharmaceutically acceptable carrier or diluent. In typical embodiments, the pharmaceutical composition is sterile.
In various embodiments, the pharmaceutical composition comprises the GAL9 binding molecule at a concentration of 0.1 mg/ml-100 mg/ml. In specific embodiments, the pharmaceutical composition comprises the GAL9 binding molecule at a concentration of 0.5 mg/ml, 1 mg/ml, 1.5 mg/ml, 2 mg/ml, 2.5 mg/ml, 5 mg/ml, 7.5 mg/ml, or 10 mg/ml. In some embodiments, the pharmaceutical composition comprises the GAL9 binding molecule at a concentration of more than 10 mg/ml. In certain embodiments, the GAL9 binding molecule is present at a concentration of 20 mg/ml, 25 mg/ml, 30 mg/ml, 35 mg/ml, 40 mg/ml, 45 mg/ml, or even 50 mg/ml or higher. In particular embodiments, the GAL9 binding molecule is present at a concentration of more than 50 mg/ml.
In various embodiments, the pharmaceutical compositions are described in more detail in U.S. Pat. Nos. 8,961,964, 8,945,865, 8,420,081, 6,685,940, 6,171,586, 8,821,865, 9,216,219, U.S. application Ser. No. 10/813,483, WO 2014/066468, WO 2011/104381, and WO 2016/180941, each of which is incorporated herein in its entirety.
In another aspect, methods of treatment are provided, the methods comprising administering a GAL9 binding molecule as described herein to a patient with a disease or condition in an amount effective to treat the patient.
In some embodiments, the subject can be a mammal. In some embodiments, the mammal is a mouse. In a preferred embodiment, the mammal is a human.
The GAL9 binding molecule can be used alone or in combination with other therapeutic agents or procedures to treat or prevent a disease or condition. The GAL9 binding molecule can be administered either simultaneously or sequentially with a second therapeutic agent, dependent upon the disease to be treated.
In some embodiments, the anti-GAL9 binding molecules is used in combination with an agent or procedure that is used in the clinic or is within the current standard of care to treat or prevent a disease or condition, such as proliferative disease or cancer. In some embodiments, the GAL9 binding molecule is administered in combination with an immune checkpoint inhibitor, such as an anti-PD-L1 antibody, anti-PD-1 antibody, anti-CTLA4 antibody, anti-LAB3 antibody, anti-TIM1 antibody, anti-TIGIT antibody, anti-PVRIG antibody.
In some embodiments, the treatment comprises administration one or more GAL9 binding molecule as described herein to a subject with a proliferative disease in an amount effective to treat the subject.
In some embodiments, the treatment comprises administration of an effective amount of one or more GAL9 binding molecules as described herein for the treatment of cancer and/or precancer. In some embodiments, the treatment comprises administration of an effective amount of one or more GAL9 binding molecules as described herein, in combination with another cancer therapeutic and/or treatment regimen (radiation, surgery, or the like, etc.).
In various embodiments, the cancer is a cancer of the bladder, blood, bone, bone marrow, brain, breast, colon, esophagus, gastrointestinal, gum, head, kidney, liver, lung, nasopharynx, neck, head and neck, ovary, prostate, pancreas, skin, stomach, testis, tongue, or uterus.
In some embodiments, the cancerous or pre-cancerous tumor is a neoplasm, malignant tumor, carcinoma, undifferentiated tumor, giant and spindle cell carcinoma, small cell carcinoma, papillary carcinoma, squamous cell carcinoma, head and neck squamous cell carcinoma, lymphoepithelial carcinoma, basal cell carcinoma, pilomatrix carcinoma, transitional cell carcinoma, papillary transitional cell carcinoma, adenocarcinoma, gastrinoma, malignant, cholangiocarcinoma, hepatocellular carcinoma, combined hepatocellular carcinoma and cholangiocarcinoma, trabecular adenocarcinoma, adenoid cystic carcinoma, adenocarcinoma in adenomatous polyp, adenocarcinoma, familial polyposis coli, solid carcinoma, carcinoid tumor, malignant, branchiolo-alveolar adenocarcinoma, papillary adenocarcinoma, chromophobe carcinoma, acidophil carcinoma, oxyphilic adenocarcinoma, basophil carcinoma, clear cell adenocarcinoma, granular cell carcinoma, follicular adenocarcinoma, papillary and follicular adenocarcinoma, nonencapsulating sclerosing carcinoma, adrenal cortical carcinoma, endometroid carcinoma, skin appendage carcinoma, apocrine adenocarcinoma, sebaceous adenocarcinoma, ceruminous adenocarcinoma, mucoepidermoid carcinoma, cystadenocarcinoma, pancreatic adenocarcinoma, pancreatic ductal adenocarcinoma, cystadenocarcinomas, pancreatic neuroendocrine tumors (PanNETs), adenosquamous carcinomas of the pancreas, signet ring cell carcinomas of the pancreas, hepatoid carcinomas of the pancreas, colloid carcinomas of the pancreas, undifferentiated carcinomas of the pancreas, and undifferentiated carcinomas with osteoclast-like giant cells of the pancreas, acinar cell carcinomas of the pancreas, solid pseudopapillary neoplasms of the pancreas, pancreatoblastoma, rare exocrine cancers of the pancreas, pancreatic serous cystadenomas, pancreatic mucinous cystic neoplasms, papillary cystadenocarcinoma, papillary serous cystadenocarcinoma, mucinous cystadenocarcinoma, mucinous adenocarcinoma, signet ring cell carcinoma, infiltrating duct carcinoma, medullary carcinoma, lobular carcinoma, inflammatory carcinoma, Paget's disease, mammary, acinar cell carcinoma, adenosquamous carcinoma, adenocarcinoma w/squamous metaplasia, thymoma, malignant, ovarian stromal tumor, malignant thecoma, malignant granulosa cell tumor, malignant androblastoma, malignant sertoli cell carcinoma, leydig cell tumor, malignant lipid cell tumor, malignant paraganglioma, malignant extra-mammary paraganglioma, malignant pheochromocytoma, glomangiosarcoma, malignant melanoma, amelanotic melanoma, superficial spreading melanoma, melanoma in giant pigmented nevus, epithelioid cell melanoma, blue nevus, malignant sarcoma, fibrosarcoma, fibrous histiocytoma, malignant myxosarcoma, liposarcoma, leiomyosarcoma, rhabdomyosarcoma, embryonal rhabdomyosarcoma, alveolar rhabdomyosarcoma, stromal sarcoma, mixed tumor, malignant mullerian mixed tumor, nephroblastoma, hepatoblastoma, carcinosarcoma, mesenchymoma, malignant brenner tumor, malignant phyllodes tumor, malignant synovial sarcoma, mesothelioma, malignant dysgerminoma, embryonal carcinoma, teratoma, malignant struma ovarii, malignant choriocarcinoma, mesonephroma, malignant hemangiosarcoma, hemangioendothelioma, malignant Kaposi's sarcoma, hemangiopericytoma, malignant, lymphangiosarcoma, osteosarcoma, juxtacortical osteosarcoma, chondrosarcoma, chondroblastoma, malignant mesenchymal chondrosarcoma, giant cell tumor of bone, Ewing's sarcoma, odontogenic tumor, malignant ameloblastic odontosarcoma, ameloblastoma, malignant ameloblastic fibrosarcoma, pinealoma, malignant chordoma, glioma, malignant ependymoma, astrocytoma, protoplasmic astrocytoma, fibrillary astrocytoma, astroblastoma, glioblastoma, oligodendroglioma, oligodendroblastoma, primitive neuroectodermal, cerebellar sarcoma, ganglioneuroblastoma, neuroblastoma, retinoblastoma, olfactory neurogenic tumor, meningioma, malignant, neurofibrosarcoma, neurilemmoma, malignant granular cell tumor, malignant lymphoma, Hodgkin's disease, Hodgkin's paragranuloma, malignant lymphoma, small lymphocytic, malignant lymphoma, large cell, diffuse, malignant lymphoma, follicular, mycosis fungoides, other specified Non-Hodgkin's lymphomas, malignant histiocytosis, multiple myeloma, mast cell sarcoma, immunoproliferative small intestinal disease, leukemia, lymphoid leukemia, plasma cell leukemia, erythroleukemia, lymphosarcoma cell leukemia, myeloid leukemia, basophilic leukemia, eosinophilic leukemia, monocytic leukemia, mast cell leukemia, megakaryoblastic leukemia, myeloid sarcoma, or hairy cell leukemia.
In some embodiments, the cancer is a viral-induced cancer, for example, a cancer caused by an infection from a oncovirus or a tumor virus (which are also known as a “cancer virus”). In some embodiments, the cancer virus is a DNA virus. In some embodiments, the cancer virus is an RNA virus.
In some embodiments, the cancerous or pre-cancerous tumor is associated or caused by a cancer virus. Non-limiting examples of a cancer virus include: a Epstein-Barr virus (EBV), a Hepatitis B virus, a Hepatitis C virus, a Human papilloma virus, a Human T-lymphotropic virus 1 (HTLV-1), a Kaposi sarcoma associated-herpesvirus (KHSV), a Merkel cell polyomavirus, or a Cytomegalovirus.
In some embodiments, the cancerous or pre-cancerous tumor is associated or caused by a cancer virus that directly induces transformation of the infected host cell, thereby regulating the host cell's growth and survival or alternatively initiating a DNA damage response which in turn increases genetic instability and accelerates the acquisition of the cancer causing mutations in the genome of the host cell.
In some embodiments, the cancerous or pre-cancerous tumor is associated or caused by a cancer virus that induces chronic inflammation in a host. For example, infections with HBV and HCV can induce chronic liver inflammation associated with oxidative DNA damage followed by cirrhosis resulting in some cases in the development of hepatocellular carcinoma.
In some embodiments, the cancerous or pre-cancerous tumor is associated or caused by a cancer virus that is not oncogenic but inhibits the host's immune system, disrupting immunosurveillance and thereby allowing for the emergence of mutated malignant cells, for example HIV-infected patients.
In some embodiments, the treatment comprises administration one or more GAL9 binding molecules as described herein to a subject with an infectious disease(s), such as infection with HIV, HCV, HBV, EBV, or HPV.
In some embodiments, the treatment comprises administration one or more GAL9 binding molecules as described herein to a subject with HIV or AIDs in an amount effective to treat the subject.
The GAL9 binding molecule may be administered to a subject by any route known in the art. For example, the GAL9 binding molecule is administered to a human subject via, e.g., intravenous, subcutaneous, intramuscular, intradermal, intraarterial, intraperitoneal, intranasal, parenteral, pulmonary, topical, oral, sublingual, intratumoral, peritumoral, intralesional, intrasynovial, intrathecal, intra-cerebrospinal, or perilesional administration. The GAL9 binding molecule may be administered to a subject per se or as a pharmaceutical composition. Exemplary pharmaceutical compositions are described herein.
The following examples are provided by way of illustration, not limitation. In particular, the methods for the expression and purification of the various antigen-binding proteins and their use in various assays as described in more detail below are non-limiting and illustrative.
Various antigen-binding proteins tested were expressed using the Expi293 transient transfection system according to manufacturer's instructions (Thermo Fisher Scientific). Briefly, plasmids coding for individual chains were mixed at 1:1 mass ratio, unless otherwise stated, and transfected into Expi 293 cells with ExpiFectamine 293 transfection kit. Cells were cultured at 37° C. with 8% CO2, 100% humidity and shaking at 125 rpm. Transfected cells were fed once after 16-18 hours of transfections. The cells were harvested at day 5 by centrifugation at 2000 g for 10 minutes. The supernatant was collected for affinity chromatography purification.
Various GAL9 antigen-binding proteins are tested and expressed using the ExpiCHO transient transfection system according to manufacturer's instructions. Briefly, plasmids coding for individual chains are mixed at, for example, a 1:1 mass ratio, and transfected with ExpiFectamine CHO transfection kit into ExpiCHO.
Cells are cultured at 37° C. with 8% CO2, 100% humidity and shaking at 125 rpm. Transfected cells are generally be fed once after 16-18 hours of transfections. The cells are harvested at day 5 by centrifugation at 2000 g for 10 munities. The supernatant is then collected for affinity chromatography purification.
Cleared supernatants containing the various antigen-binding proteins were separated using either a Protein A (ProtA) resin or an anti-CH1 resin on a Gravity flow purifier. In examples where a head-to-head comparison was performed, supernatants containing the various antigen-binding proteins were split into two equal samples. For ProtA purification, a 1 mL Protein A column (GE Healthcare) was equilibrated with PBS (5 mM sodium potassium phosphate pH 7.4, 150 mM sodium chloride). The sample was loaded onto the column at 5 ml/min. The sample was eluted using 0.1M sodium acetate pH 3.5. The elution was monitored by absorbance at 280 nm and the elution peaks were pooled for analysis. The elution was monitored by absorbance at 280 nm and the elution peaks were pooled for analysis.
Samples containing the various separated antigen-binding proteins were analyzed by reducing and non-reducing SDS-PAGE for the presence of complete product, incomplete product, and overall purity. 2 μg of each sample was added to 15 μL SDS loading buffer. Reducing samples were incubated in the presence of 10 mM reducing agent at 75° C. for 10 minutes. Non-reducing samples were incubated at 70° C. for 5 minutes without reducing agent. The reducing and non-reducing samples were loaded into a 4-15% gradient TGX gel (BioRad) with running buffer and run for 30 minutes at 220 volts. Upon completion of the run, the gel was washed with deionized (DI) water and stained using GelCode Blue Safe Protein Stain (ThermoFisher). The gels were destained with DI water prior to analysis. Densitometry analysis of scanned images of the destained gels was performed using standard image analysis software to calculate the relative abundance of bands in each sample.
Samples containing the various separated antigen-binding proteins were analyzed by cation exchange chromatography for the ratio of complete product to incomplete product and impurities. Cleared supernatants were analyzed with a 5-ml MonoS (GE Lifesciences) on an AKTA Purifier FPLC. The MonoS column was equilibrated with buffer A (10 mM MES pH 6.0). The samples were loaded onto the column at 2 ml/min. The sample was eluted using a 0-30% gradient with buffer B (10 mM MES pH 6.0, 1 M sodium chloride) over 6 column bed volumes (CV). The elution was monitored by absorbance at 280 nm and the purity of the samples were calculated by peak integration to identify the abundance of the monomer peak and contaminants peaks. The monomer peak and contaminant peaks were separately pooled for analysis by SDS-PAGE as described above.
Analytical SEC Chromatography of each sample at 1 mg/mL was loaded onto the column at 1 ml/min. The sample was eluted using an isocratic flow of PBS for 1.5 CV. The elution was monitored by absorbance at 280 nm and the elution peaks were analyzed by peak integration.
Samples containing the various separated antigen-binding proteins were analyzed by mass spectrometry to confirm the correct species by molecular weight. All analysis was performed by a third-party research organization. Briefly, samples were treated with a cocktail of enzymes to remove glycosylation. Samples were tested in the reduced format to specifically identify each chain by molecular weight and under non-reducing conditions to identify the molecular weights of all complexes in the samples. Mass spec analysis was used to identify the number of unique products based on molecular weight.
Phage display of human Fab libraries was carried out using standard protocols. Human GAL9 protein was purchased from Acro Biosystems (Human Gal9 His-tag Cat #LG9-H5244) and biotinylated using EZ-Link NHS-PEG12-Biotin (ThermoScientific Cat #21312) using standard protocols. Phage clones were screened for the ability to bind the GAL9 protein by phage ELISA using standard protocols.
Briefly, Fab-formatted phage libraries were constructed using expression vectors capable of replication and expression in phage (also referred to as a phagemid). Both the heavy chain and the light chain were encoded for in the same expression vector, where the heavy chain was fused to a truncated variant of the phage coat protein pIII. The light chain and heavy chain-pIII fusion were expressed as separate polypeptides and assembled in the bacterial periplasm, where the redox potential enables disulfide bond formation, to form the phage display antibody containing the candidate ABS.
The library was created using sequences derived from a specific human heavy chain variable domain (VH3-23) and a specific human light chain variable domain (Vκ-1). For the screened library, all three CDRs of the VH domain were diversified to match the positional amino acid frequency by CDR length found in the human antibody repertoire. Light chain variable domains within the screened library were generated with diversity introduced solely into the VL CDR3 (L3); the light chain VL CDR1 (L1) and CDR2 (L2) retained the human germline sequence.
The heavy chain scaffold (SEQ ID NO:2), light chain scaffold (SEQ ID NO:4), full heavy chain Fab polypeptide (SEQ ID NO:1), and full light chain Fab polypeptide (SEQ ID NO:3) used in the phage display library are shown below, where a lower case “x” represents CDR amino acids that were varied to create the library.
Diversity was created through Kunkel mutagenesis using primers to introduce diversity into VH CDR1 (H1), VH CDR2 (H2), VH CDR3 (H3) and VL CDR3 (L3) to mimic the diversity found in the natural antibody repertoire, as described in more detail in Kunkel, TA (PNAS Jan. 1, 1985. 82 (2) 488-492), incorporated herein by reference in its entirety. Briefly, single-stranded DNA was prepared from isolated phage using standard procedures and Kunkel mutagenesis was carried out. Chemically synthesized DNA was then electroporated into MC1061F-cells. Phagemid obtained from overnight culture was digested with restriction enzymes (Bam HI and Xba I) to remove the wild-type sequence. The digested sample was electroporated into TG1 cells, followed by recovery. Recovered cells were sub-cultured and infected with M13K07 helper phage to produce the phage library.
Phage panning was performed using standard procedures. Briefly, the first round of phage panning was performed with target immobilized on streptavidin magnetic beads which were subjected to ˜5×1012 phages from the prepared library in a volume of 1 mL in PBST-2% BSA. After a one-hour incubation, the bead-bound phage were separated from the supernatant using a magnetic stand. Beads were washed three times to remove non-specifically bound phage and were then added to ER2738 cells (5 mL) at OD600˜0.6. After 20 minutes, infected cells were sub-cultured in 25 mL 2×YT+ Ampicillin and M13K07 helper phage (final concentration, ˜1010 pfu/ml) and allowed to grow overnight at 37° C. with vigorous shaking. The next day, phage were prepared using standard procedures by PEG precipitation. Pre-clearance of phage specific to SAV-coated beads was performed prior to panning. The second round of panning was performed using the KingFisher magnetic bead handler with 100 nM bead-immobilized antigen using standard procedures. In total, 3-4 rounds of phage panning were performed to enrich in phage displaying Fabs specific for the target antigen. Target-specific enrichment was confirmed using polyclonal and monoclonal phage ELISA. DNA sequencing was used to determine isolated Fab clones containing a candidate ABS.
The VL and VH domains identified in the phage screen described above were reformatted into a bivalent monospecific native human full-length IgG1 architecture.
Native Human Full-Length IgG1 Light Chain Architecture:
Equivalent to phage display light chain Fab, see [SEQ ID NO:3].
To measure qualitative binding affinity in the GAL9 binder discovery campaigns, IgG1 reformatted binders were immobilized to a biosensor on an Octet (Pall ForteBio) biolayer interferometer.
Soluble GAL9 antigen was then added to the system and binding measured. Qualitative binding affinity was assessed by visualizing the slope of the dissociation phase of the octet sensogram from weakest (+) to strongest (+++). A slow off rate represented by a negligible drop in the dissociation phase of the sensogram and indicated a tight binding antibody (+++). To obtain accurate kinetic constants for monovalent affinities, a dilution series involving of at least five concentrations of the GAL9 analyte (ranging from approximately 10 to 20× KD to 0.1× KD value, 2-fold dilutions) were measured in the association step. In the dissociation step, the sensor was dipped into buffer solution that did not contain the GAL9 analyte, permitting the bound complex on the surface of the sensor to dissociate. Octet kinetic analysis software was used to calculate the kinetic and equilibrium binding constants based on the rate of association and dissociation curves. Analysis was performed globally (global fit) where kinetic constants were derived simultaneously from all analyte concentration included in the experiment.
Anti-GAL9 candidates formatted into a bivalent monospecific native human full-length IgG1, as described above, were tested for GAL9 binding in a pair-wise manner using an octet-based ‘tandem’ assay. Briefly, biotinylated GAL9 was immobilized on a streptavidin sensor and two anti-GAL9 candidates were bound in tandem. A competitive blocking profile was generated determining whether a given anti-GAL9 candidate blocked binding of a panel of other anti-GAL9 candidates to GAL9. Anti-GAL9 candidates that competed for the same or non-overlapping binding regions were grouped together and referred to as belonging to the same bin.
Individual aliquots of PepMix HCMVA (pp65) (>90%) Protein ID: P06725 (Cat. No. PM-PP65-2, JPT Peptide Technologies) were prepared according to manufacturer's instructions. PepMix™ HCMVA (pp65) is a complete protein-spanning mixture of overlapping 15mer peptides of the 65 kDa phosphoprotein (pp65) (Swiss-Prot ID: P06725) of human cytomegalovirus (HHV-5). Aliquots of PepMix were used for immunostimulation of PBMCs to assess immune cell responses.
Frozen human peripheral blood mononuclear cells (PBMCs) were thawed according to standard conditions, then resuspended in growth media (10% FBS in RPMI).
Resuspended PBMCs were seeded at 5×105 cells in 96-well plates. Cells were incubated with 2 μg/mL PepMix™ HCMVA (pp65) plus 40 μg/mL of candidate GAL9 antibodies or control antibodies in growth media for 24 hours at 37° C., 5% CO2.
Cytokine secretion by PBMCs and by specific immune cell subpopulations was assessed by cytokine bead array at 24 hours and 72 hours after PBMC activation by PepMix HCMVA (pp65) and Galectin 9 antibody treatment as follows.
200 μl cell culture supernatant was collected and centrifuged to pellet cell debris. The resulting supernatants were analyzed using the LEGENDplex™ Human Th1 Panel (5-plex) (Cat. No. 740009, Biolegend). The LEGENDplex™ Human Th1 Panel is a bead-based assay to allows for simultaneous quantification of human cytokines IL-2, IL-6, IL-10, IFN-γ and TNF-α using flow cytometry.
Briefly, cytokine standards and capture bead mixtures were prepared according to manufacturer's instructions. Assay master mixes of 1:1:1 capture bead mixture: biotinylated detection antibodies, and assay buffer were prepared.
12.5 μl of supernatant samples or cytokine standards were incubated with 37.5 μl assay master mix. Plates were sealed, covered with foil, and shaken at 600 rpm for 2 hours at room temperature. Wells were then incubated, with shaking at 600 rpm, with streptavidin-phycoerythrin (SA-PE) for 30 minutes at room temperature. Beads were then washed twice and resuspended before proceeding to flow cytometry analysis according to manufacturer's instructions.
Following PBMC activation and Galectin 9 antibody treatment as described above, PBMC immune cells were stained with marker antibodies according to the following procedures.
Cells were resuspended at 5×106 cells/mL in growth media (10% FBS in RPMI). 200 μL of resuspended cells were aliquoted to 96 well plates, then incubated with Fixable Viability Dye eFluor® 780 for 30 minutes at 2-8° C. to irreversibly label dead cells. Cells were then washed and then incubated with human Fc Block solution (Cat. No. 14-9161-73, eBiosciences) for 10 minutes at room temperature.
An antibody cocktail working solution was prepared according to the following table.
Wells were incubated with 10 μL of diluted antibody cocktail for 30 minutes at 2-8° C. Cells were then washed and resuspended and analyzed by flow cytometry analysis.
To analyze immune stimulatory markers CD27, CD40L, ICOS, 4-1BB, and OX40 the same protocol provided above was followed but cells were incubated with the alternative antibody cocktail as detailed in Table 2 below:
A chemically synthetic Fab phage library with diversity introduced into the Fab CDRs was screened against GAL9 antigens using a monoclonal phage ELISA format as described above. Phage clones expressing Fabs that recognized GAL9 were sequenced.
The campaign initially identified 52 GAL9 binding candidates (antigen binding site clones). Functional assays conducted after the variable regions of these clones had been reformatted into a bivalent monospecific human IgG1 format identified 22 antibodies having immune activating properties.
Table 3 lists the VH CDR1/2/3 sequences from the 22 activating ABS clones, showing only the residues of the CDRs that had been varied in constructing the library. Table 4 lists the VL CDR1/2/3 sequences from the identified ABS clones; the light chain CDR1 and CDR2 sequences are invariant, and only the residues of CDR3 that were varied in constructing the library are shown.
Table 5 presents the full CDR sequences, according to multiple art-accepted definitions, for the 22 candidate anti-GAL9 immune-activating antibodies.
Table 6 presents full immunoglobulin heavy chain and full immunoglobulin light chain sequences, and the VH and VL. sequences, of various ABS candidates formatted into a bivalent monospecific human full-length IgG1 architecture.
Select GAL9 binding candidates were analyzed for binding properties: cross-reactive binding with murine GAL9, qualitative binding, epitope binning (Bin 2—candidates bin with Commercial antibody Clone ECA8 from LS Bio [LS-C179448], Bin 3—candidates bin with Commercial antibody Clone ECA42 from LS Bio [LS-C179449], which is the “tool antibody” referenced in
Select GAL9 binding candidates were further analyzed for sequence motifs that could adversely affect antibody properties that are relevant to clinical development, such as stability, mutability, and immunogenicity. Computational analysis was performed according to Kumar and Singh (Developability of biotherapeutics: computational approaches. Boca Raton: CRC Press, Taylor & Francis Group, 2016). Analysis results are presented in Table 8, and demonstrate a limited number of adverse sequence motifs are present in the listed clones, indicating the potential for further clinical development.
1(NG, NS, NA, NH, ND)
2(DG, DP, DS)
3(DP, DY, HS, KT, HXS, SXH)
4(NXS/T)
5(LLQG (SEQ ID NO: 1121), HPQ, FHENSP (SEQ ID NO: 1122), LPRWG (SEQ ID NO: 1123), HHH)
63% in at least 2 of DRB1_0101, DRB1_0301, DRB1_0401, DRB1_0701, DRB_1101, DRB1_1301, DRB1_1501, DRB1_0801
Candidate GAL9 ABSs were formatted into a bivalent monospecific native human full-length IgG1 heavy chain and light chain architectures (SEQ ID NO:5 and SEQ ID NO: 3, respectively) and were tested for their effect on cytokine production by PBMCs following peptide stimulation. PBMCs were stimulated essentially as described in Section 6.11.1 above. Briefly, PBMCs were harvested from human donors known to be responsive to human CMV virus (HCWV), placed in culture, and stimulated with HCMV PepMix to prime an antigen specific response, and treated with one of: control IgG, a comparator tool activating mAb (clone ECA42), α-PD1 (Nivolumab), or candidate anti-GAL9 antibodies. Cytokine secretion was measured at 24 and 72 hrs post-treatment by bead cytokine array. Results for INF-γ and TNF-α are depicted in
Notably, PBMCs treated with candidates P9-15, P9-18, P9-21, and P9-28 demonstrated improved IFN-γ and TNF-α secretion following stimulation relative to both IgG control and the GAL9 comparator Tool antibody (clone ECA42). In addition, PBMCs treated with candidates P9-15, P9-18, P9-21, and P9-28 notably also demonstrated improved TNF-α production following stimulation relative to treatment with a commercial α-PD1 antibody. Thus, treatment of PBMCs with select anti-GAL9 candidates was able to improve cytokine secretion following peptide stimulation. Treatment with P9-54 resulted in a neutral response, with no significant difference in TNF-α and IFN-γ secretion (data not shown).
Candidate GAL9 ABSs were formatted into a bivalent monospecific native human full-length IgG1 heavy chain and light chains architectures (SEQ ID NO:5 and SEQ ID NO:3, respectively) and were tested for their effect on TNF-α secretion by NK Cells (lineage, CD56+) following 72 hours of peptide stimulation. NK Cells were treated with Control Antibody Clone 55, GAL9 antibody candidate P9-15 (Clone 15), or GAL9 antibody candidate P9-18 (Clone 18), at a dosage of 5 μg or 20 μg. After treatment, cells were assessed for levels of TNF-α secretion by flow cytometry. Representative data for the percentage of NK cells (CD56+) that secreted TNF-α are presented in
Treatment with either GAL9 antibody candidate P9-18 or candidate P9-15 increased the percentages of NK cells that stained positive for TNF-α following stimulation, relative to the Clone P9-55, a negative control. In a population of NK cells treated with 5 μg of control antibody, 7.75% of such NK cells (CD56+) were TNF-α positive. By contrast, in a population of NK cells treated with 5 μg of P9-18, 12.0% of such NK cells were TNF-α positive. And NK cells treated with 5 μg of P9-15, 22.5% of such NK cells were TNF-α positive. See
In a population of NK cells treated with 20 μg of control antibody, 10.3% of such NK cells (CD56+) were TNF-α positive. By contrast, in a population of NK cells treated with 20 μg of P9-18, 16.9% of such NK cells were TNF-α positive. And NK cells treated with 20 μg of P9-15, 28.5% of such NK cells were TNF-α positive. See
Thus, treatment with select anti-GAL9 candidates was able to increase TNF-α production by NK cells following stimulation. See
Candidate GAL9 ABSs were formatted into a bivalent monospecific native human full-length IgG1 heavy chain and light chains architectures (SEQ ID NO:5 and SEQ ID NO:3, respectively) and were tested for their effect on IL-12 secretion by dendritic cells (lineage negative, class II+, CD11c+) following peptide stimulation. PBMCs, which include the population of dendritic cells (DCs), were treated as described in Example 2 then assessed for levels of IL-12 secretion using an IL-12 Secretion Assay-Detection Kit (PE), Human (Cat. No. 130-092-124, Miltenyi Biotec) as per the manufacturers protocol. Representative data for the percentage of DCs that secreted IL-12 are presented in
Notably, treatment with the GAL9 antibody candidate P9-18 increased the percentages of DCs that stained positive for IL-12 following stimulation, relative to the IgG control. In a population of DCs treated with control IgG, 0.26% of such DCs were IL-12 positive. By contrast, in a population of DCs treated with P9-18, 7.74% of such DCs were IL-12 positive, a 28-fold increase in IL-12 positive DCs relative to the IgG control-treated population. Thus, treatment of PBMCs with select anti-GAL9 candidates was able to increase IL-12 production by DCs following stimulation.
Candidate GAL9 ABSs that had been formatted into a bivalent monospecific native human full-length IgG1 heavy chain and light chain architectures (SEQ ID NO:5 and SEQ ID NO:3, respectively) were tested for their effect on immune stimulatory surface marker expression by CD8+ T-cells following peptide stimulation. PBMCs, which include the population of CD8+ T-cells, were treated as described in Example 2, stained with marker antibodies as described herein, then harvested for flow cytometry. Levels of the immune stimulatory surface markers CD27, CD42L, ICOS, 4-1BB, and X40 were assessed on CD8 T-cells. Data are shown in
Representative data for the percentage of CD8+ T-cells that stained positive for immune stimulatory surface marker are presented in Table 11 below.
Notably, PBMCs treated with candidates P9-18 or P9-21 demonstrated increased percentages of CD8+ T-cells that stained positive for the various immune stimulatory surface markers following stimulation relative to the IgG control, the GAL9 comparator Tool antibody (clone ECA42), and α-PD1, including a greater than 2-fold increase in the percentage of CD8+ T-cells that stained positive for CD40L and OX40. Thus, treatment of PBMCs with select anti-GAL9 candidates was able to improve immune stimulatory surface marker expression by CD8+ T cells following stimulation. The same immune stimulatory response was observed with low responder PBMC cells, donor 5 (data not shown).
Candidate GAL9 ABSs were formatted into a bivalent monospecific native human full-length IgG1 heavy chain and light chains architecture (SEQ ID NO:5 and SEQ ID NO:3, respectively) and were tested for their effect on PD-L1 and PD-L2 cell surface expression on dendritic cells (lineage negative, class II, CD11c+) following peptide stimulation. PBMCs, which include the population of dendritic cells (DCs), were treated as described in Example 2 then harvested for flow cytometry and the levels of PD-L1 and PD-L2 were assessed on DCs. Representative data for the percentage of DCs that stained positive for PD-L1 and PD-L2, as well as the geometric mean fluorescent intensity (GMI), are presented in Table 12 below.
Notably, PBMCs treated with candidate P9-18 demonstrated increased percentages of DCs that stained positive for PD-L2 following stimulation relative to the IgG control and the GAL9 comparator Tool antibody (ECA42). Both P9-18 and P9-21 also demonstrated a decreased percentage of PD-L1, as well as decreased Geometric Mean Fluorescence (GMI) of PD-L1 on DCs. Thus, treatment of PBMCs with select anti-GAL9 candidates was able to alter PD-L1 and PD-L2 surface expression by DCs following stimulation.
Candidate GAL9 ABSs were formatted into a bivalent monospecific native human full-length IgG1 heavy chain and light chains architecture (SEQ ID NO:5 and SEQ ID NO:3, respectively) and were tested for their effect on clustering of GAL9, PD-L1, and PD-L2 on the cell-surface of dendritic cells (“DCs”).
PBMCs, which include the population of dendritic cells (DCs), were treated as described in Example 2 then fixed for confocal imaging analysis to assess GAL9, CD11c, and PD-L2 distribution on dendritic cells.
Results/Conclusion
Confocal images of dendritic cells treated with IgG control (
Treatment with candidate P9-18 or P9-21 demonstrated co-localization and clustering of GAL9 and PD-L2 on DCs (
Anti-GAL9 candidate P9-18 was tested for its effect on cellular retention and distribution of PD-L2 and PD-L1 in tumor cells.
Antibodies
Candidate GAL9 ABSs were formatted into a bivalent monospecific native human full-length IgG1 heavy chain and light chain architecture (SEQ ID NO:5 and SEQ ID NO:3, respectively). Anti-PD-L2 clone TY25 and anti-PD-L1 clone 10F.9G2 were obtained from BioXcell (Lebanon, N.H.).
Cell Culture and Immunostaining
CT26 tumor cells were cultured and treated with either anti-GAL9 candidate P9-18 or IgG control. Cells were fixed and stained with DAPI, anti-PD-L2, and anti-PD-L1 for confocal imaging analysis.
Results/Conclusion
This study was conducted to determine if anti-GAL9 candidates P9-18 and P9-21 can inhibit tumor growth in a colon and melanoma tumor models.
Antibodies
Candidate GAL9 ABSs were formatted into a bivalent monospecific formatted on a mouse IgG2a backbone.
Animals and Treatment
BALB/c mice were implanted subcutaneously with CT26 tumor line and treated with anti-GAL9 candidates P9-18, P9-21, or IgG control. Treatments were intraperitoneal (I.P.), 200 μg, on days 7, 11, 15, and 19 with ten mice per treatment group. Tumor growth was assessed by measuring tumor volume. Mice were euthanized if tumors reached a volume of ˜1000 mm3.
C57BL/6 mice were implanted intradermally with a B16.F0 tumor line and treated with anti-GAL9 candidates P9-18, P9-21, or IgG control. Treatments were administered I.P., at 200 μg, on days 3, 7, 11, and 15, with ten mice per treatment group.
Results/Conclusion
Mice treated with P9-18 or P9-21 demonstrated a complete regression of CT26 tumors, while mice treated with the IgG control demonstrated continued tumor growth. See
This study was conducted to determine the effect of anti-GAL9 P9-15 candidate on Epstein-Barr virus (EBV)-induced tumors in a humanized mouse model.
Epstein-Barr Virus (EBV) is a γ-herpes virus that infects human B cells. However, many human viruses do not infect mice. Therefore, to test the effect of anti-GAL9 P9-15 on EBV-induced tumor, we a used a humanized mouse engrafted with human CD34+ hematopoietic stem cells to make a mouse model reconstituted with human immune system cells.
Infection of Humanized Mice and Treatment
Generation of Humanized NRG Mice (hu-NRG)
Five female NRG (NOD-Rag1null IL2rgnull, NOD rag gamma) were used for each treatment group. The Rag1null mutation renders the mice B and T cell deficient and the IL2rgnull mutation prevents cytokine signaling through multiple receptors, leading to a deficiency in functional NK cells. NRG mice are therefore extremely immunodeficient, allowing for engraftment of human CD34+ hematopoietic stem cells.
The mice were irradiated twice, 3-4 hours apart, with 275cGy per dose (total of 550cGy), injected intravenously with 5×104 CD34+ human stem cells, and then allowed to engraft for three weeks to produce the humanized NRG (“hu-NRG”) mice. The hu-NRG mice were weighed bi-weekly for 12 weeks to assess their health. In addition, tail bleeds were performed on week 4, week 8, and week 12 after administration of human CD34+ stem cells to monitor and confirm stable engraftment in the mice by flow cytometric analysis for detection of human CD45+ cells including total mononuclear cells (CD45+), T cells (CD3+) and B cells (CD19+).
Spleen Tumors
Following euthanasia, the spleens were excised and examined to determine the number of macroscopically visible tumors, cell number, and weight, except where the mice died or were euthanized for ethical reasons.
Assessment of EBV Viral Load
EBV loads in the spleen and blood were measured using real-time PCR.
Statistical Analyses
Mann-Whitney U test based on 2-sided tail was conducted using GraphPad Prism 7 Software (San Diego, Calif.).
Results/Conclusion
The spleens from mice treated with anti-GAL9 P9-15 mice showed fewer macroscopically visible tumors than spleens from mice treated with IgG control. See
In addition, treatment with P9-15 controlled the viral load by 88%. P9-15 treated mice had an average of 0.32×106 copies/μg of EBV, while the IgG treated mice had an average of 2×106 copies/μg of EBV (p-value<0.0079). See
This study was conducted to determine the effect of GAL9 P9-28 candidate on Epstein-Barr virus (EBV)-induced tumors in a humanized mouse model.
Animals, Infection of Humanized Mice and Treatment
This study was conducted as described in Example 10 above.
Results/Conclusion
Anti-GAL9 P9-28 treated mice showed no visible macroscopic tumors on the spleens compared to IgG control. See
This study was conducted to test the contribution of the Fc region to the antitumor effect of the immune-activating anti-Gal9 antibodies. In addition, a re-challenge study was conducted to determine if P9-18 or sFcP9-18 can establish antitumor immune memory.
Antibodies
P9-18 antigen-binding sites were formatted on either a murine IgG1 backbone, murine IgG2a backbone, or on a murine IgG2a backbone with Fc receptor-binding null mutations (sFc). The silent Fc (sFc) P9-18 antibody was made by making key point mutations that abrogate binding of the Fc to Fc receptors.
CT26 Cells
CT26 tumor cells were cultured in RPMI medium in a humidified incubator at 37° C., in an atmosphere of 5% CO2 and 95% air.
Mice and Treatment Schedule
Seven to ten mice were implanted subcutaneously with 1×105 CT26 tumor cells, and then treated with either control IgG (mouse IgG2a), P9-18-IgG1 (murine IgG1 backbone), FcR-silent sFcP9-18 (murine IgG2a backbone with Fc-receptor binding null mutations), or P9-18 (murine IgG2a backbone) I.P., at 200 μg on days 7, 11, 15, and 19.
Tumor Volume Growth
Mice were monitored for up to 143 days and tumors measured every 1-3 days by calipers. Tumor volume (mm3) was calculated according to the formula: tumor length×tumor width×2/2.
Complete Regression Response (CR)
Complete regression for the study was defined as a tumor volume 0 mm3 for 20 consecutive measurements during the study. Animals were scored every 1-3 days during the study for a complete regression (CR) event.
Re-Challenge of CT26 Tumors
Tumor-free mice surviving the original initial tumor clearance study were allowed to rest for 65-70 days after tumors cleared. On day 107, the animals were re-implanted with 1×105 CT26 tumor cells with no additional treatment. New control mice were given a treatment with IgG2a control on day 113. Tumors were then allowed to grow for an additional 36 days. Tumor volume was determined as described above for days 107-143.
Results/Conclusion
The results from the tumor growth study are shown in ), tumors reached 900-1000 mm3 over the initial 50-day period. In contrast, treatment with P9-18-IgG2a (
) had 77% (7/9) CR, and treatment with sFcP9-18-IgG2a (
) had 70% (7/10) CR. These results demonstrate that the Fc region of the P9-18 antibody is not required for its antitumor effect.
The P9-18 ABS reformatted into an IgG1 backbone () did not inhibit tumor growth, showing similar tumor growth to the control.
The results from the re-challenge study are shown in ) showed similar tumor growth as in the initial tumor clearance study. These data demonstrate that mice treated with P9-18 or sFcP9-18 have established anti-tumor immune memory to CT26 tumor cells following initial treatment with P9-18-IgG2a or sFc9-18-IgG2a.
Anti-GAL9 P9-18 was tested for its effect on PD-L1 and PD-L2 cell surface expression on tumor-associated dendritic cells and tumor cells.
Animals and Treatment
Three to five BALB/c mice were implanted subcutaneously with CT26 tumor cells and treated with P9-18 ABS formatted on a mouse IgG2a backbone or with mouse IgG2a control. All treatments were administered (I.P.), at 200 μg, on days 7 and 11.
Flow Cytometry
Tumors were dissected on day 13, digested, and dissociated. Next, a CD45.1+ cell population, which includes immune and tumor cells, was isolated using anti-CD45.1 magnetic beads (Miltenyi Biotec, Germany). The CD45.1+ cell population was labelled and analyzed by flow cytometry for PD-L1 and PD-L2 cell surface expression on tumor-associated dendritic cells (CD11c+) and tumor cells. The reagents used are shown in Table 13 below.
Statistical Analyses
Unpaired t test with Welch's correction was conducted using GraphPad Prism 7 Software (San Diego, Calif.).
Results/Conclusion
While various specific embodiments have been illustrated and described, the above specification is not restrictive. It will be appreciated that various changes can be made without departing from the spirit and scope of the invention(s). Many variations will become apparent to those skilled in the art upon review of this specification.
This application claims the benefit under 35 U.S.C. § 119(e) of prior co-pending U.S. Provisional Patent Application No. 62/964,487, filed on Jan. 22, 2020, U.S. Provisional Patent Application No. 62/900,105, filed on Sep. 13, 2019, and U.S. Provisional Patent Application No. 62/855,590, filed on May 31, 2019.
| Filing Document | Filing Date | Country | Kind |
|---|---|---|---|
| PCT/US2020/035399 | 5/29/2020 | WO | 00 |
| Number | Date | Country | |
|---|---|---|---|
| 62855590 | May 2019 | US | |
| 62900105 | Sep 2019 | US | |
| 62964487 | Jan 2020 | US |
